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ABSTRACT 
 
Copper (Cu) is an essential micronutrient, which operates as a cofactor of enzymes 
regulating a wide range of critical physiological processes.  However, Cu overload 
compromises the redox balance in cells and tissues causing serious toxicity. Removal 
of excess Cu from the body is driven be Cu-transporting ATPase ATP7B, which 
sequesters the potentially toxic metal and mediates its excretion into the bile.  
Mutations in the ATP7B result in Wilson disease (WD) that is caused by the toxic 
accumulation of Cu in the liver due to the loss of ATP7B function. The most frequent 
ATP7B mutant, H1069Q, still preserves a significant Cu-transporting activity, but 
undergoes retention and degradation in the endoplasmic reticulum (ER). Thus, rescue 
of ATP7B-H1069Q from the ER is expected to recover mutant function and, hence, 
would be beneficial for a large group of WD patients. Unfortunately, specific targets 
as well as safe drugs for correction of ATP7B-H1069Q mutant remain to be 
uncovered. 
Comparing interactomes of WT and H1069Q variants of ATP7B, I found HSP70 as a 
specific mutant interactor that regulates ER retention and degradation of ATP7B-
H1069Q. HSP70 suppression (with either RNAi or allosteric inhibitor) improved 
stability of the mutant and facilitated its export from the ER to the Golgi and post-
Golgi copper excretion sites. These findings prompted me to look for a safe way to 
inhibit HSP70 and rescue the ATP7B mutant. To this end several bioinformatics tools 
were employed to search for FDA-approved drugs that modulate HSP70 expression or 
exhibit structural similarity to HSP70 inhibitors. As a result, Domperidone and 
glucocorticoid receptor agonists were identified and validated as effective correctors 
of ATP7B mutant.  
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In summary, my findings suggest a key role for HSP70 in proteostasis of ATP7B-
H1069Q and revealed FDA-approved compounds as safe drugs for ATP7B mutant 
correction and, thus, for the normalization of Cu homeostasis in Wilson disease 
patients.  
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CHAPTER 1. INTRODUCTION 
 
Maintaining homeostasis of trace elements (e.g. biometals and minerals) is pivotal for 
normal physiology; imbalance in any of them may lead to pathological outcomes in 
humans (Rayman, 2012; Xu and Zhou, 2013). Trace elements play a wide number of 
important physiological roles. Therefore their imbalance leads to different diseases 
varying in degree of severity.  
Copper (Cu) is an essential trace element that is indispensable for activity of several 
vitally important enzymes (Ala et al., 2007). The redox properties of Cu allow it to be 
used as a cofactor by enzymes operating in several cellular processes, including 
respiration, iron metabolism, pigmentation, decomposition of superoxides and 
synthesis of collagens (Camakaris et al., 1999; Kim et al., 2008; Puig and Thiele, 
2002; Tapiero and Tew, 2003; Wessling-Resnick, 2002). The main human Cu-
dependent enzymes are listed in Table 1. 
However, in amounts that exceed cellular needs, Cu is highly toxic, owing its 
potential to facilitate the production of reactive oxygen species (ROS)(Stohs and 
Bagchi, 1995). ROS bind most biological structures (like lipids, and nucleic acids), 
causing direct cellular injury by inducing lipid and protein peroxidation and damaging 
nucleic acids. Indeed, excess Cu–derived oxidants cause hepatotoxicity in Wilson 
disease (Nagasaka et al., 2006).  
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Enzymes Function Consequences of 
deficiency 
Ceruloplasmin Iron and Cu transport Decreased circulating Cu 
levels, iron deficiency 
Hephaestin Iron transport Anemia 
Cytochrome C oxidase Mitochondrial respiration Hypothermia, 
muscle weakness 
Dopamine β-hydroxylase Catecholamine production Hypothermia,neurological 
defects 
Lysyl oxidase Connective tissue formation Laxity of skin and joints 
Peptidylglycine α-amidating 
monooxygenase 
Peptide amidation Neuroendocrine defects 
Superoxide dismutase Antioxidant defence Diminished protection  against 
oxidative stress 
Tyrosinase Pigment formation Hypopigmentation of hair and 
skin 
Sulfhydryl oxidase Cross-linking of keratin Abnormal hair, Dry skin 
 
Table 1. Function of Cu-dependent enzymes.  
Adapted from P. de Bie  et al. 2007 
Organisms have evolved homeostatic mechanisms to regulate uptake, distribution, 
use, storage, detoxification and efflux of Cu. The failure of these regulatory 
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mechanisms manifests as severe and debilitating diseases. These disorders can be 
divided into two major classes: 
1. Diseases associated with Cu deficiency, such as Menkes disease (OMIM 
#309400; Menkes et al., 1962) occipital horn syndrome (OMIM #304150) and 
distal motor neuropathy, also called as distal spinal muscular atrophy-3 or 
SMAX3 (OMIM #300489; Kaler, 2013). 
2. Diseases associated with Cu excess, such as Wilson disease (OMIM 
#277900), Indian childhood cirrhosis (OMIM #215600; Tanner, 1998) and 
idiopathic Cu toxicosis (OMIM #215600; Muller et al., 1998). 
To introduce this thesis, I would like to describe the molecular mechanisms 
behind the pathogenesis of Wilson disease, and how Cu homeostasis is impaired 
in this disease. 
 
1.1 Cu distribution in tissues 
The average daily intake of Cu varies between 1 and 3 mg and is sufficient for human 
body needs. Dietary Cu is primarily absorbed through the intestinal epithelium. Cu is 
exported from the enterocytes into the blood by Cu-ATPase ATP7A (Monty et al., 
2005; see Fig. 1). In Menkes disease, ATP7A is inactivated and Cu export from 
enterocytes is greatly impaired. As a result, Cu accumulates in intestinal cells and less 
Cu is delivered to the blood, resulting in restricted Cu supply to other tissues 
(Kodama et al., 1993). The majority of Cu that absorbed by the intestinal epithelium 
arrives to the liver through the portal vein. The liver plays a central role in  Cu 
homeostasis. Hepatocytes load adsorbed Cu onto newly-synthesized serum protein 
ceruloplasmin. In this way liver distributes Cu to the systemic circulation to provide 
tissues with the required amount of the metal (Linder et al., 1998). Hepatocytes also 
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excrete excess Cu to the biliary flow and in this way facilitate removal of the metal 
from the body.  
Cu uptake into the liver does not appear to be highly regulated. In contrast, the export 
of Cu from the liver represents a tightly regulated Cu-dependent process, which is 
driven by Cu-transporting ATPase ATP7B (Fig. 1). Failure of biliary Cu excretion 
leads to toxic accumulation of metal in the liver of patients with Wilson disease, 
Indian childhood cirrhosis or idiopathic Cu toxicosis (Fig. 1). 
  
                       
 
 
 
 
 
 
 
 
Adapted from  Lutsenko, et al.  2007 
 
Fig. 1. Schematic representation of the physiology of Cu homeostasis. Cu is exported from the enterocytes into 
the blood by Cu-ATPase ATP7A in a process that involves trafficking of the transporter towards the basolateral 
membrane. In Menkes disease, ATP7A is inactivated and Cu export from the enterocytes is greatly impaired. The 
majority of Cu that emerges from the intestinal epithelium into the blood is delivered to the liver, and less to 
kidney and other tissues. The liver is the central organ of Cu homeostasis and is primarily responsible for the 
export of excess Cu  out of the body. The export of Cu from the liver is a regulated Cu-dependent process, which 
is mediated by a Cu-transporting ATPase ATP7B. 
12	
	
Fig. 2. Schematic depiction of Cu 
distribution in a mammalian cell. 
 Cu, taken up via CTR1 (red), is transferred 
to chaperones ATOX1, CCS and COX17, 
which ferry it (black dash arrows) to 
ATP7A/B (blue) in the Golgi, to Cu–Zn 
superoxide dismutase (magenta) in the 
cytosol and to cytochrome c oxidase (green) 
in the mitochondria, respectively. In the 
Golgi, ATP7A/B load Cu on newly 
synthesized cuproenzymes (orange ball), 
which traffic along the biosynthetic pathway 
(orange arrow). Significant increase in intra- 
cellular Cu induces export of ATP7A/B (blue 
arrow) toward post- Golgi compartments and 
plasma membrane where ATP7A/B drive the 
efflux of excessive Cu from the cell.	
1.2 Cellular Cu homeostasis  
Refined mechanisms have evolved to regulate Cu homeostasis at the cellular level. Cu 
import into the cells mainly takes place via high affinity Cu transporters 1 and 2 
(CTR1, CTR2) (Moller et al., 2000; van den Berghe et al., 2007; Zhou and Gitschier, 
1997). After entry into the cell Cu immediately binds to specific proteins, Cu 
chaperones, which distribute metal towards various intracellular destinations (Fig. 2). 
In the cytosol, Cu is utilized by a radical-detoxifying enzyme Cu, zinc-dependent 
superoxide dismutase (SOD1), which acquires Cu with the help of a Cu-specific 
metallochaperone CCS (Cu chaperone of superoxide dismutase) (Culotta et al., 1997; 
Culotta et al., 2006). Cu also enters mitochondria, where COX17 chaperone facilitates 
metal incorporation into cytochrome-c oxidase (COX). The third important 
destination of Cu in the cell is the secretory pathway (Polishchuk and Lutsenko, 
2013).  
 
 
 
 
 
 
 
 
 
 
Adapted from  Polishchuk and Lutsenko, 2013  
 
Within the secretory pathway, the trans-Golgi network (TGN) compartment harbors 
Cu-ATPase(s) (ATP7A and/or ATP7B), which receive(s) Cu from the cytosolic Cu 
chaperone Atox1 (Klomp et al., 1997; Lin et al., 1997). ATP7A and ATP7B transport 
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Cu from the cytoplasm to the TGN lumen where the metal atom is loaded onto newly 
synthesized cuproenzymes moving through the secretory pathway (Fig. 2).  
 
1.3 Functions of Cu-transporting ATPases 
The Cu-transporting ATPase, ATP7A and ATP7B, move Cu away from the cytosol 
across the membrane using the energy of ATP hydrolysis. Experimental evidence for 
the Cu-transporting function of ATP7B/ATP7A emerged in 1978. Cell culture studies 
showed that the loss of ATP7A in fibroblasts from patients with Menkes disease 
resulted in cellular Cu accumulation and Cu retention phenotype was rescued by 
overexpression of either ATP7A or ATP7B (Voskoboinik et al., 1998). The direct 
involvement of ATP7A/ATP7B in Cu translocation across the membrane was further 
demonstrated in 1998.This study showed that overexpression of ATP7A or ATP7B 
resulted in increased transport of [64Cu] into isolated membrane vesicles. Similar 
results were also obtained using purified ATP7A, which was reconstituted in soybean 
asolectin liposomes (Hung et al., 2007; Voskoboinik et al., 1998; Voskoboinik et al., 
2001). Taken together, these data suggest that both ATP7A and ATP7B work as ATP-
dependent Cu-export pumps. 
Cu ATPases have a dual function: the homeostatic function is involved in the 
regulation of cellular Cu export, while the biosynthetic function is required for the 
correct biosynthesis of Cu-dependent enzymes. The homeostatic function of 
ATP7A/ATP7B heavily relies on their ability to traffic from the TGN to the 
peripheral vesicular compartments and cell membrane where ATP7A/B facilitate 
rapid excretion of the metal from the cells.  
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At the organismal level, the post-Golgi trafficking of Cu ATPases to distinct 
apical/basolateral membranes in polarized cells and the differential expression of Cu 
ATPases in tissues and organs allow higher vertebrates to deal with systemic changes 
in Cu levels (Lutsenko, 2010; Nevitt et al., 2012). ATP7A is expressed in most tissues 
(except adult hepatocytes), but its most important function is in the small intestine. In 
enterocytes, ATP7A receives adsorbed dietary Cu and moves from the Golgi to the 
basolateral surface of the cells to release Cu toward the portal circulation (Fig. 3). 
Mutations, which result in a loss of the ATP7A protein, its transport activity or a 
failure to traffic out of the Golgi, do not allow Cu to move beyond the intestinal 
barrier. As a result, severe Cu deficiency is observed in most tissues of Menkes 
disease patients (de Bie et al., 2007; Lutsenko, 2010; Lutsenko et al., 2007). In 
contrast to ATP7A, ATP7B is highly expressed in the liver and present at lower levels 
in a few other organs (brain, eye, heart, kidney, bone and placenta (Bull et al., 1993; 
Kuo et al., 1997; Michalczyk et al., 2000). In the liver, ATP7B receives Cu from the 
portal circulation and utilizes it in the Golgi for metallation of ceruloplasmin, which 
carries the metal through the blood flow and uses Cu for regulation of iron balance. 
Cu elevation beyond a certain threshold activates ATP7B export from the Golgi to the 
endo-lysosomal structures. These endo-lysosomal structures use ATP7B to sequester 
excess Cu and then undergo tightly regulated exocytosis at the canalicular surface of 
hepatocytes to release metal into the bile and hence to eliminate it from the body 
(Polishchuk et al., 2014) (Fig. 3). In Wilson disease, the lack of ATP7B activity 
and/or trafficking induces a marked accumulation of Cu in hepatocytes, development 
of morphologic and metabolic abnormalities, culminating in liver failure (de Bie et 
al., 2007; Lutsenko, 2010; Lutsenko et al., 2007). When Cu levels in the cells 
decrease both ATP7A and ATP7B use endocytic pathway(s) to return from the 
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peripheral Cu excretion compartments back to the TGN (Polishchuk and Lutsenko, 
2013) . 
 
Adapted from  Polishchuk and Lutsenko, 2013  
Fig. 3. Schematic representation of Cu homeostasis in the body. 
Cu is absorbed through the apical CTR1 channel by the enterocytes in the small intestine and effluxed across the 
basolateral surface of these cells by ATP7A into the portal circulation. The latter process requires ATP7A 
trafficking from the Golgi to the basolateral surface of the cells (blue arrow). Lack of ATP7B function in Menkes 
disease patients (green bar) results in accumulation of Cu in the enterocytes and overall Cu deficiency in the body. 
Most of the newly absorbed Cu is normally taken up by the hepatocytes in the liver, where Cu is loaded in the 
TGN by ATP7B on newly synthesized ceruloplasmin, the principal Cu carrier in the blood. In cases of Cu 
overload, ATP7B traffics to Cu excretion sites (orange arrow), i.e. apical (canalicular) membrane and associated 
vesicular structures. Mutations in the ATP7B gene that affect activity and trafficking of the corresponding protein 
block Cu delivery to ceruloplasmin and its efflux into the bile (red bars). As a result, Cu accumulates in the liver 
and causes its toxicosis in Wilson disease patients.  
 
Studies of Menkes and Wilson diseases also provided a growing body of evidences 
regarding biosynthetic roles of ATP7A/B. Loss of function of several cuproenzymes 
represents a characteristic feature of both Menkes and Wilson disease. Using 
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fibroblast isolated from patients with Menkes disease, it has been shown that ATP7A 
deficiency results in reduced activities of the Cu-dependent enzymes such as lysyl 
oxidase and tyrosinase (Petris et al., 2000; Royce et al., 1980). In its turn ATP7B 
dysfunction causes dramatic reduction in serum caeruloplasmin levels as a result of 
rapid degradation of the Cu-free form of caeruloplasmin secreted from hepatocytes of 
patients with Wilson disease (Riordan and Williams, 2001; Scheinberg and Gitlin, 
1952) .  
The first evidence for ATPase-mediated Cu transport into the secretory pathway was 
obtained in 1995 in the yeast Saccharomyces cerevisiae, which express an 
ATP7B/ATP7A orthologue, known as Ccc2p (Yuan et al., 1995). Ccc2p is localized in 
the late Golgi apparatus, where it provides Cu for Fet3p (a Cu-dependent metallo-
oxidase that is involved in iron uptake). Genetic deletion of Ccc2p suppresses Cu 
incorporation into Fet3p and impairs iron uptake, as illustrated by the inability of 
ΔCcc2 to grow under iron-limiting conditions (Yuan et al., 1995). Overexpression of 
either ATP7B or ATP7A can rescue Fet3p activity, and therefore the growth of the 
Ccc2 knockout yeast on iron-deficient media, making this a good model to study Cu-
transporting ATPase-dependent cuproenzyme biosynthesis (Yuan et al., 1995). 
Using this Ccc2 knockout complementation assay, the effects of Wilson disease and 
Menkes disease mutations on translocation of Cu into TGN lumen and subsequent 
incorporation of Cu in cuproenzymes have been determined. Indeed, it was 
demonstrated that several Menkes and Wilson disease mutations decrease or even 
completely abrogate the ability of ATP7A or ATP7B to rescue Fet3p biosynthesis or 
the Ccc2 knockout growth phenotype (Yuan et al., 1995).  
Taken together, these studies suggest that ATP7A and ATP7B play a critical role in 
both delivery of Cu to the TGN and subsequent cuproenzyme biosynthesis. Moreover, 
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these results indicate that mutations in ATP7A and ATP7B that perturb this process 
account for many of the clinical symptoms of Menkes and Wilson disease. 
 
1.4 Wilson disease 
Wilson disease (WD) is an autosomal recessive disorder with an estimated incidence 
between 1:7000 and 1:30000 (Bandmann et al., 2015). As mentioned above WD is 
caused by mutations in ATP7B, which drives excretion of Cu at the biliary domain of 
hepatocytes. Indeed, the clinical features of WD result from the toxic accumulation of 
Cu, primarily in the liver and the brain, and include: hepatic abnormalities (cirrhosis 
and chronic hepatitis, culminating in progressive liver failure) (Fig. 4), neurological 
defects (Parkinsonian features, seizures), and psychiatric symptoms (personality 
changes, depression, psychosis) (Ala et al., 2007; Gitlin, 2003).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4: Organs involved in Wilson Disease. In Wilson Disease patients Cu accumulates in several 
organs: Liver, Central nervous system, Eyes, Heart, Bone, Placenta, Blood and Kidney. 
 
Adapted from eurowilson site (http://www.eurowilson.org/en/professional/clinical-
presentation/index.phtml) 
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WD may present symptomatically at any age, although the majority presents between 
ages 5 and 35. The diagnosis of Wilson disease is determined by the presence of the 
signs and symptoms noted previously, in conjunction with laboratory tests that 
indicate impaired hepatic Cu metabolism. The clinical hallmark of Wilson disease is 
the Kayser–Fleischer ring, which is present in 95% of patients with neurologic 
symptoms and somewhat over half of those without neurologic symptoms. Neurologic 
signs are variable, most often tremor, ataxia, and dystonia.  
A peculiarity of WD is that it exhibits highly heterogeneous phenotypes, even 
between patients who have the same mutations. Differences have been found in age at 
presentation, severity of the disease and the predominance of hepatic versus 
neurological symptoms (Riordan and Williams, 2001). 
 
1.5. Impact of WD-causing mutations on ATP7B function. 
ATP7B is a complex multispan membrane protein (Fig. 5A) that belongs to a P1B-
type ATPase family. The N-terminal portion of ATP7B contains six metal binding 
domains (MBDs) followed by eight transmembrane domains that form a Cu 
translocation pathway to move Cu from the cytosol across the membrane at the 
expense of ATP hydrolysis. Autophosphatase, nucleotide binding and 
phosphorylation domains in 2nd and 3rd cytosolic loops coordinate the catalytic 
activity of ATP7B. 
A number of mutations that affect ATP7B results in lower catalytic activity and/or 
several trafficking defects, namely: (i) retention of the mutant within the ER due to 
mis-folding, (ii) failure to exit the Golgi in response to increasing Cu, (iii) constant 
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targeting to post-Golgi sites even at low Cu levels and (iv) loss of apical polarized 
targeting (fig. 5B) (de Bie et al., 2007). The localization of these mutations along the 
protein backbone frequently helped to reveal the role of several domains in the 
ATP7B function and trafficking. 
 
(A) Adapted from Polishchuk and Lutsenko, 2013 (B) Adapted from  De Bie  and Klomp, 
2007 
Fig. 5: (A) Structure of Cu-translocating ATPase. Three-dimensional representation of the Wilson 
(ATP7B) Cu-ATPase. Protein is predicted to have eight transmembrane (TM) domains, with most of 
the protein on the cytoplasmic side. ATP7B protein contains ATP-binding (red), phosphatase (green), 
and phosphorylation (blue domain), which regulate catalytic activity. N-terminal region comprises six 
Cu binding motifs that interact with Cu chaperonins and presumably deliver Cu to the channel. In 
addition, CPC motif in the 6th transmembrane domain plays a key role in Cu translocation along the 
channel, while LL signal in the C-tail is required for ATP7A/B endocytosis. (B) Schematic 
representation of Cu‐ induced relocalisation of ATP7B. The figure represents the hepatocyte. Cu 
enters through the Cu transporter 1 (CTR1), and is then distributed via the Cu chaperone ATOX1 to 
ATP7B residing in the TGN. After a rise in Cu concentrations, ATP7B relocalise from the TGN to the 
cell periphery, and also the plasma membrane, to facilitate excretion of Cu. In the hepatocyte Cu is 
excreted at the apical side into the bile. The numbers indicate localisation defects of ATP7B due to 
WD-causing mutations: (1) lack of Cu responsiveness, resulting in constitutive localisation at the TGN, 
(2) constitutive localisation at the cell periphery, and (3) mislocalisation at the ER, presumably due to 
misfolding. 
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1.5.1. ATP7B mutants with impaired Cu-dependent trafficking 
The ability to traffic in response to Cu was acquired by ATP7B during the course of 
evolution. Yeast control their intracellular Cu balance predominantly through the 
transcription of genes functioning in Cu uptake, efflux and storage rather than through 
repositioning of the proteins between different compartments (Nevitt et al., 2012). In 
contrast to ATP7B, yeast homolog Ccc2 does not traffic in response to increasing Cu 
and remains in the Golgi compartment where Ccc2 operates, almost exclusively, in 
biosynthetic processes (Yuan et al., 1997). In comparison to mammalian orthologues, 
Ccc2 has only 2 MBDs in its N-terminal part (instead of 6 in ATP7A/B). Thus, it 
turns out that domains, missing in yeast Ccc2, enable ATP7B to traffic in response to 
altering Cu levels. Indeed, MBD 5 or 6 seems to be indispensable for Cu-dependent 
export of ATP7B from the TGN (Cater et al., 2004; Strausak et al., 1999). Several 
Wilson disease missense mutations of ATP7B have also been mapped to this region 
(Guo et al., 2005). 
Catalytic phosphorylation is also required for post-Golgi trafficking of Cu pumps. As 
part of their catalytic cycle the Cu P-type ATPases undergo transient auto-
phosphorylation at the invariant aspartate residue in DKTG motif to form an acyl-
phosphate intermediate (Inesi et al., 2014; Tsivkovskii et al., 2002). For both ATP7A 
and ATP7B, formation of this intermediate depends on Cu (Petris et al., 2002) and 
appears to be essential for the Cu-dependent relocalization of the proteins (Bartee and 
Lutsenko, 2007). Several ATP7A/B variants with mutations in the regions which 
coordinate ATP binding and hydrolysis, fail to relocate from the TGN to Cu excretion 
sites (Petris et al., 2002). As an example, the WD-causing E1064A mutation in the 
nucleotide binding domain disrupts the catalytic activity of ATP7B and strongly 
inhibits its export from the TGN in response to Cu overload (Morgan et al., 2004). 
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Interestingly, the neighbouring H1069Q mutation results in completely different 
ATP7B localization within the ER (see below) indicating that even mutations within 
the same domain may have a diverse impact on trafficking/activity of Cu ATPases. 
On the other hand, dephosphorylation of the aspartate in DKTG stretch supports 
retrograde trafficking of Cu ATPases to the Golgi. Inhibition of the auto-phosphatase 
activity through mutation in the phosphatase domain strongly impairs retrieval of both 
ATP7A and ATP7B to the Golgi when Cu levels decrease (Petris et al., 2002). 
 
1.5.2 Endocytic ATP7B mutants 
Another key determinant for retrieval of ATP7B to the Golgi is a tri-leucine signal in 
the C-tail. Such leucine-based signal undergoes recognition by adaptor proteins that 
drive clathrin-mediated endocytosis of membrane proteins (Traub and Bonifacino, 
2013). Substitution of these leucines with alanines results in ATP7B arrest in 
peripheral endocytic compartment and reduced retrieval of ATP7B to the Golgi even 
in the case of decrease in intracellular Cu levels (Cater et al., 2006). No WD-causing 
mutations were detected within LLL motif of ATP7B.  However, several mutations 
may affect recognition of LLL signal in C-tail region of ATP7B. ATP7BL1373P/R 
mutants reside in the peripheral endocytic structures and do not return to the Golgi 
even when Cu is deprived. These mutations may destabilize C-tail of ATP7B and, 
hence, prevent recognition of leucine-based sorting signals. As a result, these mutants 
instead of being sorted to the Golgi are directed towards lysosomes, where undergo 
rapid degradation (Braiterman et al., 2011). A similar mechanism is likely to cause 
trafficking aberrations in WD-causing ATP7B mutants with C-terminal truncations at 
the positions Q1399, W1410 and P1438 (Braiterman et al., 2011). Although these 
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mutants seem to be catalytically active, their faster degradation and reduced amount 
in the TGN (where ceruloplasmin is metallated) can contribute to WD symptoms. 
 
1.5.3. ATP7B mutants with compromised apical/canalicular targeting 
To provide efficient excretion of excess Cu into the bile, ATP7B trafficking has to be 
directed to the apical/canalicular domain in hepatocytes (Nyasae et al., 2014). The N-
terminal portion of ATP7B plays a crucial role in apical delivery of the protein as it 
contains 37FAFDNVGYE45 apical targeting signal (Nyasae et al., 2014). In addition 
the N-terminal part participates in ATP7B interaction with the p62/DNCT4 subunit of 
dynactin/dynein motor  complex (Lim et al., 2006; Polishchuk et al., 2014), which 
move ATP7B endo-lysosomal organelles (frequently called “vesicles”) to the 
canalicular surface in response to Cu overload (Polishchuk et al., 2014). WD-
associated N41S mutation resides within apical sorting signal and causes basolateral 
mistargeting of ATP7B in hepatocytes (Braiterman et al., 2009). A number of other 
mutations in the N-terminal part of ATP7B were detected in WD patients. A few of 
them cause ER retention of ATP7B, while it remains to be determined whether others 
compromise apical delivery of the protein.  
 
1.5.4. ER retention of ATP7B mutants 
The most frequent ATP7B mutations, H1069Q (40%-75% in the white population) 
and R778L (10%-40% of the Asian patients), result in ATP7B proteins with 
significant residual activities (Forbes and Cox, 1998; Iida et al., 1998; van den Berghe 
et al., 2009), which, however, are strongly retained in the endoplasmic reticulum (ER) 
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(Payne et al., 1998).  Notably, many other WD-causing ATP7B mutants with 
substantial Cu-translocating activity undergo complete or partial arrest in the ER 
(Efremov et al., 2004; Harada et al., 2005; Harada et al., 2000; Huster et al., 2012; 
Lutsenko and Petris, 2003; Morgan et al., 2004; Petris et al., 2002; Vanderwerf and 
Lutsenko, 2002; Voskoboinik et al., 2001). Thus, although potentially able to 
transport Cu, these mutants cannot reach the Cu excretion sites to remove excess Cu 
from hepatocytes. ER retention of such ATP7B mutants occurs due to their mis-
folding (Huster et al., 2012; Payne et al., 1998) and increased aggregation 
(D'Agostino et al., 2013), and hence is due to their failure to fulfil the requirements of 
the ER quality control machinery. As a result, the cellular proteostatic network may 
recognize ATP7B mutants as defective and direct them towards the ERAD pathway, 
as in the case of the most frequent ΔF508-CFTR mutant in cystic fibrosis (van den 
Berghe et al., 2009). Therefore, identifying molecular targets for recovery of partially- 
or fully-active ATP7B mutants from the ER to appropriate functional compartment(s) 
would be beneficial for WD patients with such mutations. 
 
1.6 Correction of ATP7B mutants as a potential therapeutic 
approach for WD 
Existing treatment of Wilson disease mainly relies on two strategies: increasing Cu 
excretion from the body, and reducing Cu absorption from the diet (Ala et al., 2007). 
The first strategy is mainly represented by Cu chelation therapy, using penicillamine, 
trientine (Walshe, 1956a, b) or ammonium tetrathiomolybdate (Brewer et al., 1991). 
Cu chelators act by ligating Cu and promoting its urinary excretion. These chelators 
have been shown to effectively ameliorate hepatic and neuropsychiatric signs in large 
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cohort of patients and to prevent the onset of disease in asymptomatic individuals 
(Brewer et al., 1994). The second therapeutic strategy requires treatment with zinc 
salts, which results in decreased intestinal absorption of Cu. Zinc acts by inducing the 
expression of metallothionein, which capture dietary Cu in enterocytes and inhibits its 
entry into the portal circulation. In circumstances of advanced liver failure, due to 
delayed diagnosis, poor compliance with treatment, or rapid, fulminant hepatitis, 
mortality is almost certain without hepatic transplantation. Currently, about 5% of 
patients with Wilson disease require liver transplantation for their survival (Schilsky 
et al., 1994). 
Although clearly effective, existing treatments have serious toxicities, including 
hypersensitivity reactions, bone marrow suppression, and the development of 
autoimmune disease. In addition recent study suggests that about 33% of patients with 
Wilson disease do not respond to either Zn or Cu chelators (Roberts et al., 2008). 
Moreover, the morbidity and mortality of liver transplantation remains substantial, 
and this should be considered as a viable treatment option only in life-threatening 
circumstances (Schilsky et al., 1994). Taken together, there is a clear demand for 
novel treatment strategies for patients with Wilson disease. 
 
Importantly, most ATP7B mutations belong to missense (58%) or small 
deletion/insertion (27%) categories (Hsi et al., 2004) and frequently result in aberrant 
protein products, which still exhibit residual Cu-transporting activity, but due to 
misfolding undergo strong retention and degradation in the ER (Forbes and Cox, 
1998; Iida et al., 1998; van den Berghe et al., 2009). This is the case for the most 
frequent ATP7B mutants H1069Q (40-50% in European and North American 
patients) and R778L (40% in East Asian patients) (Gomes and Dedoussis, 2016). 
25	
Therefore correction of such mutants to appropriate intracellular localization in the 
Golgi complex is expected to recover Cu homeostasis and, hence, to alleviate WD 
symptoms in large cohort of patients.  
In recent years, several attempts have been made in this direction, with the use of 
pharmachochaperones such as curcumin and phenylbutyrate (van den Berghe et al., 
2009). These drugs were shown to reduce the degradation of several ER-retained 
mutants of ATP7B (van den Berghe et al., 2009), while their potential for correction 
of mutant localization remains to be demonstrated. Several ATP7B interactors have 
also been reported to modulate the degradation of the ATP7B mutants and/or their 
retention in the ER. These include COMMD1 (de Bie et al., 2007), clusterin (Materia 
et al., 2011) and CRYAB (D'Agostino et al., 2013). So their potential as therapeutic 
targets could be explored.  
 
Our recent study indicates that the expression of ER-retained ATP7B mutants triggers 
the activation of the p38 and JNK stress kinase pathways (Chesi et al., 2016). p38 and 
JNK accelerate arrest and further degradation of the ATP7B mutants in the ER 
through the cluster of downstream effectors regulating ER quality control processes 
(Concilli et al., 2016). Thus, suppression of p38 and JNK signaling renders ER quality 
control machinery less stringent towards aberrant ATP7B variants and allows mutants 
to escape towards the Golgi and post-Golgi compartments. As a result, the delivery of 
the ATP7B mutant to the Cu excretion sites strongly attenuates the toxic 
accumulation of the metal (Chesi et al., 2016). Therefore, targeting the ER quality 
control system emerges as a promising approach for the correction of the ATP7B 
mutant and cure of Wilson disease. 
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1.7 Proteomic as an effective approach in discovery of targets for 
pathogenic mutant correction. 
Unfortunately, in contrast to the similar Δ508F mutant of the CFTR, the regulation of 
the proteostatic network dealing with ATP7B mutants remains poorly understood and 
requires new approaches to detect targets for safe mutant correction (Klomp et al., 
1997). For this reason, changes in the interactome of ATP7B that are caused by WD-
associated mutation(s) deserve a detailed analysis, which is likely to reveal potential 
candidates to rescue localization and function of aberrant ATP7B variants. A similar 
approach has already been used to find key novel interactors, whose loss promotes 
∆F508 CFTR channel function in cystic fibrosis epithelia (Pankow et al., 2015). In 
general, mass spectrometry (MS)-based quantitative proteomic strategies are used to 
study protein alterations in different biological states (Trinkle-Mulcahy et al., 2008). 
Among these strategies, stable isotope labeling by amino acids in cell culture 
(SILAC) is most widely used for comparative proteomics. In SILAC, proteins in cell 
populations are metabolically encoded with 'heavy' isotopes of lysine and arginine 
and are used as internal standards for relative quantification of differentially altered 
proteins. Characterizing protein–protein interactions (PPIs) helped to discover new 
pathways of disease progression, thereby aiding diagnostic and preventative 
strategies. Hosp et al. (Hosp et al., 2015) took this approach, using quantitative 
interaction proteomics to develop interactome maps for a number of 
neurodegenerative diseases (NDDs) as Alzheimer’s disease (AD), Parkinson’s 
disease, Huntington’s disease and spinocerebellar ataxia type 1. Hosp et al. (Hosp et 
al., 2015) examined interactomes associated with both wild type and disease-
associated variants. Thus, comparing interactomes of wild type with disease-specific 
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ATP7B isoforms, I hoped to gain insight in functional proteostatic changes that 
contribute to WD pathogenesis as well as to find key binding partners that could be 
utilized for ATP7B mutant correction. 
1.8  Project rationale and summary 
It is known that a residual Cu-translocating activity (5-10%) is sufficient for the 
rescue of Cu homeostasis if an ATPase mutant can be targeted to where the Cu 
transport is required (Iida et al., 1998; Kaler, 2013; Rodriguez-Granillo et al., 2008; 
Tsivkovskii et al., 2003). Therefore, correction of the trafficking and localization of 
the ATP7B mutants should (at least partially) allow the recovery of the normal Cu 
metabolism that is affected in Wilson disease, and this would be beneficial for the 
large cohort of patients with this pathology. 
Here, I used traditional and SILAC proteomic analyses to find specific ATP7B-
H1069Q interactors that can be targeted for correction of this mutant. Using this 
approach I identified HSP70 as the most evident mutant specific binding partner, 
which when suppressed (by either RNAi or allosteric inhibitor) allows the mutant to 
circumvent ER retention and degradation. Considering the importance of HSP70 for 
several key homeostatic processes such as protein folding and quality control, 
prevention of aggregation, transport and regulation of proteins, signal transduction 
and apoptosis (Bukau et al., 2006; Frydman, 2001; Hartl et al., 2011; Kettern et al., 
2010; Mayer and Bukau, 2005; Pratt and Toft, 2003; Tyedmers et al., 2010), I 
attempted to find safe drugs that would inhibit HSP70 activity/expression without 
significant impact on cell/organism health. To this end the TIGEM Bioinformatics 
Core searched in available databases for FDA-approved drugs that reduce HSP70 
expression or exhibit structural similarity to HSP70 inhibitors. Among couple of 
hundreds of potential candidates resulting from this analysis, we found that 
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Mometasone  (MF), Dexamethasone (Dexa), Beclomethasone (Beclo) and 
Domperidone (Domp.) reduce ATP7B mutant degradation and improve delivery of 
ATP7B-H1069Q to the Golgi membranes, where wild type ATP7B (ATP7B-WT) 
normally operates.  
In summary, I found 4 FDA-approved drugs for ATP7B-H1069Q correction using 
combination of proteomics and bioinformatics approaches. Moreover my study 
revealed HSP70 as an attractive target for the correction of Wilson disease mutants, 
and for the development of new therapeutic strategies for the treatment of patients 
with Wilson disease.  
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CHAPTER 2. MATERIALS AND METHODS 
2.1 Cell culture 
All cell lines were maintained in a humidified 5% CO2 atmosphere at 37 ºC, and 
passaged upon reaching ~80% confluency. To passage cells, the growth medium was 
aspirated off the adherent cell population, and the cells were rinsed with PBS and then 
harvested by incubation in Trypsin/EDTA (Invitrogen), according to the appropriate 
cell line. HeLa and HepG2 cells were grown in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% (v/v) fetal calf serum (decomplemented at 56 °C 
for 30 min for HepG2 cells), 2 mM L-glutamine, penicillin and streptomycin. HepG2 
cells with knock out of ATP7B gene (HepG2-KO) and stable ATP7B mutant hepatic 
cell lines (Chandhok et al., 2016; Chandhok et al., 2014) were grown in RPMI 1640 
Medium supplemented with 10% (v/v) fetal calf serum, 2 mM L-glutamine, penicillin 
and streptomycin. 
2.2 Generation of Recombinant Adenoviruses 
Generation of recombinant first generation human type 5 adenovirus containing 
DNAs encoding either ATP7B-WT-GFP or ATP7B-H1069Q-GFP was performed by 
Vector biolabs (Philadelphia, PA, USA). To sub-clone the entire expression cassette, 
the following oligonucleotides were used:   
SV40revAscI (5'- AATGGCGCGCCTAAGATACATTGATGAGTTTGGA -3') and  
CMVfwAscI (5'- TCCGGCGCGCCTGTTATTAATAGTAATCAATTACGG -3').  
Cells were infected with adenovirus carrying ATP7B-WT-GFP or ATP7B-H1069Q-
GFP respectively with a different Multiplicity Of Infection (MOI) depending on the 
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cell type. Generation of control helper-dependent adenovirus containing GFP (HDAd-
GFP) was performed by the adenoviral core at Tigem. HDAd-GFP was produced in 
116 cells with the helper virus AdNG163 as described previously (Palmer and Ng, 
2003; Suzuki et al., 2010) . 
2.3 RNA interference 
Small interfering RNA (siRNA) oligonucleotides targeting the HSPA1A/B, were 
purchased from Sigma-Aldrich (St. Louis, USA). Following siRNA were utilized: 
si HSPA1A/B -1 SASI_Hs01_00051449 CUUUCCAGGUGAUCAACGA   
si HSPA1A/B -2 SASI_Hs01_00051450 AGGACGAGUUUGAGCACAA 
Scrambled siRNAs were used as a control. HepG2 or HeLa cells were transfected with 
siRNA using Darmafect4 (Dharmacon, Pittsburgh, USA) or Oligofectamine TM 
Reagent (Invitrogen, Carlsbad, USA) respectively according to manufacturer’s 
instructions. SiRNA-treated cells were prepared for Q-PCR, Western Blot and 
confocal microscopy (see below) to analyze the efficiency of silencing and the 
intracellular distribution of ATP7B-WT-GFP or ATP7B-H1069Q-GFP.  
2.4 RNA Preparation and Q-PCR 
The efficiency of silencing was checked using QRT-PCR. For this, the total RNAs 
from control cells and silenced HeLa cells infected with Adenoviruses carrying 
ATP7B-WT-GFP and ATP7B-H1069Q-GFP were purified using the QIA shredder 
and extracted using the RNeasy Protect Mini Kit. The total RNA was converted into 
cDNA using the QuantiTect Reverse Transcription Kit. Q-PCR experiments were 
performed using the LightCycler 480 SYBR Green MasterMix for cDNA 
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amplification and the LightCycler 480 II for signal detection. The Q-PCR results were 
analyzed using the comparative Ct method normalized against the housekeeping gene 
β-actin. SiRNA-treated cells were prepared for confocal microscopy to analyze the 
intracellular distribution of ATP7BWT and mutant. 
ATP7B forward (5'- TCTCTGGTCATCCTGGTGGTT-3')  
ATP7B reverse (5'- GGGCTTCTGAGGTTTTGCTCT-3') 
 
2.5 Immunoprecipitation and Traditional Mass Spectrometry 
Analysis 
To identify the interactors of ATP7B-WT and ATP7B-H1069Q in liver cell line 
regular  proteomics analysis was performed in collaboration with the Proteomics 
facility at CEINGE (Naples, Italy).  
To immunoprecipitate ATP7B-H1069Q-GFP or ATP7B-WT-GFP HepG2 cells were 
transduced with corresponding adenoviruses. Then cell lysates were incubated for 
overnight at 4°C with the anti-GFP Antibody A-11120 (Thermo Fisher Scientific, 
MA, USA)  and protein A Sepharose P9424 (Sigma, St Louis, MO, USA) for 5 hours. 
The beads were resuspended in sample loading buffer and loaded onto 12% SDS-
PAGE. 
The gel was stained with Coomassie colloidal blue (Pierce). Protein bands were 
excised from the gel and destained by repeated washings with 50 mM NH4HCO3 pH 
8.0, and acetonitrile. Samples were reduced and carboxyamidomethylated with 10 
mM DTT and 55 mM iodoacetamide in 50 mM NH4HCO3 buffer, pH 8.0. Tryptic 
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digestion of the alkylated samples was performed at 37 °C overnight, using 100 ng 
trypsin. 
MALDI mass spectra were recorded on an Applied Biosystems Voyager DE-PRO 
mass spectrometer equipped with a reflectron TOF analyser and used in delayed 
extraction mode. One µl of peptide mixture was mixed with an equal volume of α-
cyano-4-hydroxycynnamic acid as matrix (in acetonitrile/50 mM citric acid [70:30, 
v/v]), applied to the metallic sample plate and air dried. Mass calibration was 
performed using the standard mixture provided by the manufacturer. Raw data, 
reported as monoisotopic masses, were then introduced into the MASCOT peptide 
mass fingerprinting search programme (Matrix Science, Boston, USA) and used for 
protein identification. 
LC-MS/MS analyses were performed on a CHIP MS Ion Trap XCT Ultra equipped 
with a 1100 HPLC system and a chip cube (Agilent Technologies, Palo Alto, CA, 
USA). After loading, the peptide mixture (10 µl in 0.2% formic acid) was first 
concentrated and washed at 4 µl/min in a 40 nL enrichment column (Agilent 
Technologies chip), with 0.1% formic acid as eluent. The sample was then 
fractionated on a C18 reverse-phase capillary column (75 µm x 43 mm) onto the CHIP 
(Agilent Technologies chip) at a flow rate of 200 nl/min, with a linear gradient of 
eluent B (0.2% formic acid in 95% acetonitrile) in A (0.2% formic acid in 2% 
acetonitrile) from 7% to 60% in 50 min. Peptide analysis was performed using data-
dependent acquisition of one MS scan (mass range from 400 to 2000 m/z) followed 
by MS/MS scans of the three most abundant ions in each MS scan. Raw data from 
nanoLC-MS/MS analyses were introduced into the MASCOT software (Matrix 
Science, Boston, USA) to search a non-redundant protein database. The specific 
interactors for ATP7B-WT and ATP7B-H1069Q are listed in fig. 8.  
33	
 
2.6 SILAC Proteomics Analysis 
To evaluate quantitative differences in ATP7B-H1069Q and ATP7B-WT 
interactomes I performed Stable isotope labeling by amino acids in cell culture 
(SILAC) (Ong et al., 2002) proteomics analysis in collaboration with Oxford 
University Proteomics Facility (Oxford, UK).  
HepG2 cells transduced with ATP7B-WT-GFP, ATP7B-H1069Q-GFP or GFP 
(control) adenoviruses were grown in cell culture medium supplemented with 
different arginine and lysine isotopes. DMEM containing medium R6K4, heavy 
R10K8 or light R0K0 isotopes (Dundee cell products, Dundee, United Kingdom) and 
supplemented with 10% SILAC dialysed FCS was supplied to ATP7B-H1069Q-GFP, 
ATP7B-WT-GFP or GFP expressing cells respectively for six passages. 
Lysates from HepG2 cells expressing ATP7B-H1069Q-GFP, ATP7B-WT-GFP or 
GFP alone were mixed at 1:1:1 ratio. An immunoprecipitation of GFP-tagged protein 
from lysate mixture and further gel preparation for proteomics analysis was 
performed as described in the previous section. 
Protein bands were excised from the gel and send to Proteomics Oxford Facility to 
proceed with digestion  Nano-LC/MSMS and analysis of relative expression level of 
proteins. 
Peptides were resuspended in 10% formic acid. They were separated on an Ultimate 
3000 UHPLC system (Thermo Fischer Scientific) and electrosprayed directly into a 
QExactive mass spectrometer (Thermo Fischer Scientific) through an EASY-Spray 
nano-electrospray ion source (Thermo Fischer Scientific). The peptides were trapped 
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on a C18 PepMap100 pre-column (300µm x 5mm,100Å, Thermo Fisher Scientific) 
using solvent A (0.1% Formic Acid in water) at a pressure of 500 bar. The peptides 
were separated on a PepMapRSLC C18 column (2um, 100Å, 75umx50cm, Thermo 
Fisher Scientific) using a linear gradient (length: 120 minutes, 7% to 28% solvent B 
(0.1% formic acid in acetonitrile), flow rate: 200 nL/min). The raw data was acquired 
on the mass spectrometer in a data-dependent mode (DDA). Full scan MS spectra 
were acquired in the Orbitrap (scan range 350-2000 m/z, resolution 70000, AGC 
target 3e6, maximum injection time 50 ms). After the MS scans, the 20 most intense 
peaks were selected for HCD fragmentation at 30% of normalised collision energy. 
HCD spectra were also acquired in the Orbitrap (resolution 17500, AGC target 5e4, 
maximum injection time 120 ms) with first fixed mass at 180 m/z. On the basis of 
Mass Spectrometry Analysis several parameters like score, coverage and number of 
peptides were considered, most importantly the ratio between Heavy/Light, 
Medium/Light and Medium/Heavy was calculated. 
2.7 Western Blotting  
Cells grown in 6-well plates were placed on ice and washed twice with ice-cold Tris-
buffered saline (TBS), incubated with lysis buffer (0.5 % Triton X-100, 20 mM 
Tris/HCl (pH 7.4), 150 mM NaCl, 1mM EDTA (pH: 8), 0.5% NP-40, 10% glycerol, 
supplemented with 1× protease inhibitor cocktail (Sigma), scraped and transferred 
into a pre-cooled microcentrifuge tube. Samples were spun down at 13,200 rpm for 15 
min and the supernatants were transferred to fresh tubes, while the pellets were 
discarded. A small volume of each lysate was removed to determine protein 
concentration using Bradford reagent (Biorad, California, United States). 80 µg of 
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each sample were taken and added to SDS sample buffer. Each cell lysate was boiled 
in sample buffer at 95°C for 5 min and centrifuged at 13,200 rpm for 1 min. 
Equal amounts of protein (80 µg) were loaded into the wells of a S600 Hoefer 
Apparatus  SDS-PAGE gel, along with molecular weight markers. The gel was run 
for 45 min at 35 mA and then the strength of an electric current was increased to 40 
mA to finish the run in about 3 h 30 min. A 10% gradient gel was used to separate 
proteins that have to be detected.  
The membrane was stained with Ponceau solution to check the transfer quality and 
then washed with 5% glacial acetic acid. The blot was rinsed 3 times for 5 min with 
TBST and then blocked in 1% BSA in PBS or 5% milk in TBST at RT for 1 hr. The 
membrane was incubated with primary antibody of interest for 1 hour at RT, rinsed 
with TBST and incubated with secondary antibodies for 45 min at RT. Finally the blot 
was rinsed with TBST and TBS for further analysis. 
Antibodies used are : anti-GFP (kindly provided from De Matteis’s lab), Anti-α 1 
Sodium Potassium ATPase antibody [464.6] - Plasma Membrane Marker (ab7671), 
anti-HSP90  4874S Cell Signaling, anti-GAPDH (6C5) sc32233 from Santa Cruz, 
anti-α Tubulin  T5168 from Sigma, anti-actin (A2066) from Sigma, HRP-conjugated 
secondary antibody Goat Anti-Mouse IgG, H and L Chain Specific Peroxidase 
Conjugate (401215; Calbiochem) to reveal: GAPDH, α-Tubulin, α 1 Sodium 
Potassium ATPase  proteins and HRP-conjugated secondary antibody Goat Anti-
Rabbit IgG, H and L Chain Specific Peroxidase Conjugate (401315; Calbiochem) to 
reveal: GFP, Actin and HSP90 proteins. 
The blot was incubated with chemiluminescent substrate Pierce ECL Western 
Blotting Substrate (32106, Thermo Scientific) according to the manufacturer’s 
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instruction. Chemiluminescent signals were captured using Chemidoc Amersham 
Imager 600 and the loading control protein levels: GAPDH  or α-tubulin or actin 
protein were used to normalize the target protein levels. 
2.8 Gene ontology enrichment and STRING analysis  
To evaluate gene ontology enrichments in ATP7B-WT or ATP7B-H1069Q 
interactomes the specific binding partners of the WT protein or of the mutant were 
entered into the Gene Functional Annotation Tool that is available at the Database for 
Annotation Visualisation and Integrated Discovery (DAVID) website 
(http://david.abcc.ncifcrf.gov) by using their official gene symbols. The gene 
ontology (GO) options GOTERM_BP_ALL, GOTERM_MF_ALL, 
GOTERM_CC_ALL were selected for enrichment analyses and a functional 
annotation chart was generated. A maximum  p -value of 0.01 was chosen to select 
only the significant categories. In addition, to analyze connections between specific 
interactors of ATP7B mutant the STRING 9.1 database was used (Franceschini et al., 
2013). 
2.9 Proximity ligation assay (PLA) 
In-situ ATP7B-GFP and HSPA1A/B interaction, revealed as red fluorescent dots, was 
detected using the Duolink II PLAkit (Olink Bioscience, Uppsala, Sweden), according 
to the manufacturer’s instructions. As a positive control, cells were infected with 
ATP7B-H1069Q-GFP and labelled with an anti-p62 antibody (Dynactin p62 
Antibody (H-4): sc-55603) from Santa Cruz in combination with an anti-GFP 
antibody (Polishchuk et al., 2014). As a negative control, cells were infected with 
ATP7B-H1069Q-GFP and labeled with an anti-GFP antibody in combination with the 
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antibody against the luminal domain of transferrin receptor (TfR) (Invitrogen) to 
demonstrate no interaction between  ATP7B-GFP and TfR (D'Agostino et al., 2013). 
In the case of HSPA1A/B was used Anti-HSP70 antibody [C92F3A-5] (ab47455) by 
Abcam. Coverslips were stained with Hoechst, mounted in Mowiol and analyzed by 
confocal immunofluorescence microscopy. 
2.10 Immunofluorescence 
Cells were fixed for 10 min with 4% paraformaldehyde (PFA) in 0.2 M HEPES 
followed by incubation with blocking/permeabilizing solution (0.5% bovine serum 
albumin (BSA), 0.1% saponin, 50 mM NH4Cl in PBS) for 20-30 min. Primary and 
secondary antibodies were diluted in blocking/permeabilizing solution and added to 
the cells for 1h  or 45 min respectively. Samples were examined with a ZEISS LSM 
700 or LSM 710 confocal microscopes equipped with a 63X 1.4 NA oil objective. 
Images were processed using Photoshop CS3. 
The antibodies used in immunofluorescence experiments are the following: anti-
MRP2 (Enzo Life Sciences, Lausanne, Switzerland), anti-TGN46 (AbD Serotec, 
Oxford, UK) anti-human LAMP1 (H4A30) from Developmental Studies Hybridoma 
Bank, Iowa City, USA) and secondary Alexa Fluor 568-conjugated antibodies 
(Invitrogen-Life Technologies, Grand Island, NY, USA). 
Morphometric analysis shows the percentage of cells (average ± SD, n=10 fields) 
with ATP7B mutant in the ER. 
2.11 Statistical Analyses 
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Data are expressed as mean values ± SD. Statistical significance was computed using 
the Student’s two-tail t test. A p value < 0.05 was considered statistically significant. 
In all figures, ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001. Experiment was done in 
triplicate. Mean ± SD. 
2.12 Cu-dependent trafficking of ATP7B  
To compare trafficking of ATP7B-WT and ATP7B-H1069Q in high and low Cu 
conditions, cells were treated with 200 µM of CuSO4 for 2 or 8 hours in HeLa and 
HepG2 cells. After Cu treatment the cells were prepared for either surface 
biotinylation (in the case of HeLa) or Immunofluorescence (both HeLa and HepG2). 
2.13 Cell surface biotinylation  
HeLa cells were used to evaluate delivery of either ATP7B-WT-GFP or ATP7B-
H1069Q-GFP to the plasma membrane using cell surface biotinylation. To this end 
the cells were infected with adenovirus carrying either ATP7B-WT-GFP or ATP7B-
H1069Q-GFP. The day after infection cells were rinsed twice with PBS containing 
0.1 mM CaCl2 and 1 mM MgCl2  followed by two successive 20 min incubations with 
0.5 mg/ml EZ-Link Sulfo-NHS-Biotin (Pierce) diluted in PBS. The biotinylation 
reaction was stopped by washing the cells with PBS/NH4Cl quenching solution for 10 
min. Cells were then solubilized in a lysis buffer containing 0.5 % Triton X-100, 20 
mM Tris/HCl (pH 7.4), 150 mM NaCl, 1mM EDTA (pH: 8), 0.5% NP-40, 10% 
glycerol, supplemented with 1× protease inhibitor cocktail (Sigma). The mixture was 
placed into a microfuge tube, kept on ice for 10 min, and then spun at 14 000 rpm for 
15 min at 4°C. 
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 The lysate was incubated with streptavidin beads (Pierce) at 4°C overnight. After 
incubation, beads were pelleted by centrifugation at 4000 rpm for 1min. The beads 
were then washed in lysis buffer (20 mM HEPES pH 7.4, 150 mM NaCl, 10% 
glycerol, 0.1% Triton X-100), supplemented with 1× protease inhibitor cocktail. 
Biotinylated proteins were eluted with SDS sample buffer, containing 100 mM β-
mercaptoethanol and analyzed by immunoblot analysis.  
The primary antibodies used are: anti-GFP (kindly provided from De Matteis’s lab), 
Anti-α 1 Sodium Potassium ATPase antibody [464.6] - Plasma Membrane Marker 
(ab7671), anti-HSP90 (4874S) Cell Signaling, anti-GAPDH (6C5) sc32233, anti-α 
Tubulin  T5168 from Sigma, anti-actin (A2066) from Sigma. 
The secondary antibodies used were: HRP-conjugated secondary antibody Goat Anti-
Mouse IgG, H and L Chain Specific Peroxidase Conjugate (401215; Calbiochem) to 
reveal: GAPDH, α-tubulin, α 1 Sodium Potassium ATPase  proteins and HRP-
conjugated secondary antibody Goat Anti-Rabbit IgG, H and L Chain Specific 
Peroxidase Conjugate (401315; Calbiochem) to reveal: GFP, Actin and HSP90 
proteins. 
2.14 Immunoprecipitation  
Immunoprecipitation to test specific interactions between ATP7B-H1069Q-GFP and 
HSPA1A/B was as follows. Cell lysates from HeLa cells (1 mg) were incubated with 
1.5 µg anti-GFP antibody (GFP Tag Antibody (A-11120) Thermo Fisher) overnight at 
4°C. Then, protein A Sepharose beads (Sigma) were added to each specimen for 4 
hours at 4°C and immune complexes were collected by centrifugation. The beads 
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were then washed and immunoprecipitated proteins were eluted, separated by SDS-
PAGE and analyzed by Western blot. 
 
 2.15 Treatments with drugs 
To investigate localization of ATP7B-H1069Q-GFP in HeLa, HepG2 and HepG2 KO 
cells were treated with the HS-72 inhibitor, cells were treated with 10µM, 50µM and 
100 µM respectively for 24 hours at 37°C. Then cells were processed for 
immunofluorescence experiment to see whether ATP7B-H1069Q-GFP protein was 
delivered to the Golgi and vesicles in treated cells. To inhibit HSPA1A/B, specific 
inhibitor called HS-72  was added to the HeLa and HepG2 cells for 24 hours at the 
final concentrations of 10µM or 20µM, respectively. HeLa or HepG2 or HepG2 KO 
cells were infected with first generation adenovirus containing ATP7B-WT-GFP or 
ATP7B-H1069Q-GFP, respectively, with different multiplicity of infection (MOI) 
based on the physical title of Adenoviruses. To see the stabilization in time of mutant 
protein with the treatments, cells were incubated with 100 µg/ml cycloheximide at 
different times: 30 min, 1 hours and half and 5 hours and then were processed for 
Western Blot. 
To explore the effect of FDA-approved drugs on modulation of HSP70 activity  
HeLa, HepG2 and HepG2 KO cells were treated with concentration of four different 
compounds: 10-50 µM of Domperidone*, 30 µM of Mometasone*, 30 µM of 
Dexamethasone* and 1 or 10 µM of Beclomethasone* (* = Glucocorticoid agonists 
that could modulate the expression of HSP70) for 24 hours. Then, cells were analyzed 
for RT-PCR, Western blot, immunoprecipitation and immunofluorescence 
experiments. Morphometric analysis based on percentage of cells that present ATP7B 
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in the ER for immunofluorescence experiment, quantification of the bands with Image 
J for WB and immunoprecipitation experiments and fold-change percentage 
parameter of mutant protein in treated-cells  compared to the control cells  for RT-
PCR were considered to understand whether the treatments made  impact on ATP7B 
mutant localization and stabilization. 
2.16 Chemical Similarity Search 
The software FLAP v. 2.0 (Baroni et al., 2007) was used to compute and performe a 
comparison of HS-72-like FDA-approved drugs by 3D Molecular Interaction Fields 
(MIFs) (fig. 20). The program FLAP is an algorithm designed primarily for virtual 
screening, 3D QSAR, as well as pocket comparison via three-dimensional 
superposition (Sirci et al., 2012a; Sirci et al., 2012b). FLAP allows 3D molecular 
superimposition of two molecules and computes a pairwise similarity scores based on 
Molecular Interaction Fields (MIFs), in order to evaluate type, strength and direction 
of the interactions a molecule can have. The GRID tool, (Carosati et al., 2004; 
Goodford, 1985) part of the FLAP software was used to compute the Molecular 
Interaction Fields of 3D chemical structures based on three interaction probes: H, 
DRY and OH2. The hydrogen probe H is used to compute the shape of a small 
molecule. The hydrophobic probe DRY finds places at which hydrophobic atoms on 
the surface of a target molecule will make favourable interactions with hydrophobic 
ligand atoms. The probe OH2 represents polar and hydrophilic interactions mainly 
generated by hydrogen bond donor and acceptor functional groups and charges 
interactions.  
Firstly, all molecules of interest are described by the GRID force-field, and the 
resulting MIFs are reduced in complexity by extracting an adequate amount of 
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hotspots (pharmacophores) which is proportional to the strength of interaction of the 
MIF considered (Baroni et al., 2007). Susequently, four-point pharmacophores 
derived from the MIFs were iteratively extracted and used to align their 3D chemical 
structures, as performed in previuos 3D-QSAR and Virtual Screening works (Carosati 
et al., 2004; Goodford, 1985). Finally, the evaluation of MIF volume superpositions is 
reported as similarity between the different structures, ranging from 0 to 1 for each of 
the three probes. A global score (GLOB-S) is then obtained as the sum of the three 
scores of the individual probes. Higher GLOB-S values correspond to more similar 
structures. 
2.17 Bioinformatics search for FDA-approved drugs reducing HSP70 
expression 
"Connectivity Map" collection  (or CMap), a catalog of gene-expression data 
collected from human cells treated with chemical compounds and genetic reagents, 
was utilized to find drugs that probably could modulate the expression of HSP70 
protein and with the help of F. Napolitano (TIGEM Bioinformatics Core), I selected 
the most significant drugs based on their p-value. 
The database of gene expression data is made of 6,100 differential expression publicly 
available as the "Connectivity Map" collection (Lamb et al., 2006). Each gene 
expression profile was sorted so that most up-regulated genes appear at its top and 
most down-regulated genes appear at its bottom. The 6,100 sorted profiles were then 
reduced to 1,309 (one per treatment) by merging together those obtained after 
treatment with the same small molecule, as described in (Iorio et al., 2010). 
HSPA1A and HSPA1B genes were defined as the molecular targets to screen for 
HSP70 drugs that reduce expression of these genes. Among the hits we then 
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considered only compounds that increase expression of HSP90A1 and HSP90A2 (see 
Results). For the analysis the gene expression profile for each drug from the CMap 
was searched for dysregulation of each of the 4 genes. In particular, the mean rank of 
the two HSP70 targets (say r1) and the mean rank of two HSP90 targets (say r2) were 
recorded for each CMap drug. Finally, all CMap drugs were ranked according to the 
score: r1 + 1310 - r2. Top drugs in this ranking are expected to down-regulate 
HSPA1A and HSPA1B and up-regulate HSP90AA1 and HSP90AB1. 
2.18 Drug-set Enrichment Analysis (DSEA)  
In order to find which are the common pathways that are affected by FDA-approved 
drug, with the help of F. Napolitano, DSEA Analysis was performed on three different 
compound: Dexametasone, Mometasone and Beclometasone.  
 (DSEA), aims at identifying the mechanism(s) of action shared by a set of 
compounds in terms of the molecular pathways consistently targeted by most of them. 
The main hypothesis underlying DSEA is that if pharmacologically different drugs 
induce the same phenotype of interest, then some of the molecular pathways they 
target must be shared by most of them. DSEA takes advantage of a large database of 
pathways by merging 9 different publicly available collections, including generic 
gene sets (co-localised genes, coregulated genes, protein complex subunits, etc.) and 
disease-related gene sets. In order to define the list of pathways targeted by a drug, 
DSEA analyses were performed  according to the Connectivity Map dataset (Lamb et 
al., 2006), which consists of about 7000 microarray assays following treatment of four 
different cell lines with 1309 drugs. Relevant pathways for the drugs of interest are 
thus selected against the background of all the other drugs in the CMap. In this way, 
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pathways that are relevant for the phenotype of interest tend to emerge, while drug-
specific pathways, which are unrelated to the phenotype of interest, tend to cancel out. 
 
2.19 MTT assay 
Knockout cells harboring wild type ATP7B (WT ATP7B KO cells) or mutagenized 
ATP7B clones (H1069Q and R778L cells)  (Chandhok et al., 2016) were maintained 
in RPMI media (Euroclone) containing 10% fetal bovine serum (FBS) with 100 U/ml 
penicillin/streptomycin and supplemented with 6 µg/ml blasticidin (Sigma). 15x103 
cells were seeded in 96 well plates in 100 µl of complete medium. After 48h, cells 
were incubated with 10 µM Mometasone, Dexamethasone or Beclomethasone, 1 µM 
of Domperidone or 100 nM of HS-72 inhibitor, respectively. 24h later, cells were 
exposed to 1mM CuCl2 (Sigma) overnight. For the MTT (3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide) assay, cells were washed twice in PBS 
(Euroclone), resuspended in 12mM MTT (Invitrogen) dissolved in 100 µl of DMEM 
media lacking phenol red (Invitrogen) and supplemented with 10% FBS and 100 
U/ml penicillin/streptomycin and incubated for 2.5h in 5% CO2 at 37 °C. Incubation 
was stopped using 100 µl of a solution of 25% aqueous ammonia (Sigma) in DMSO 
(Sigma) for 10min in 5% CO2 at 37 °C. Absorbance was recorded at 540 nm on a 
multi-well plate reader (Synergy/neo, Biotek ) and results analyzed as percentage of 
treated compared to untreated cells (no CuCl2 considered as 100% viability). 
Differences in viability between 1mM CuCl2 treated cells and cells treated with drugs 
and 1mM CuCl2 were analysed using an T-test. A value of P<0.05 was considered 
significant. All data are presented as a mean ± SEM.  
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CHAPTER 3. RESULTS AND DISCUSSION  
3.1. HSP70 as new molecular target for the correction of Wilson 
disease mutants  
3.1.1. Traditional proteomics analysis reveals specific binding partners for 
ATP7B-WT and ATP7B-H1069Q 
To understand which molecular target(s) could be explored for the correction of WD-
causing mutants, I used proteomics approach. As outlined in the previous chapter 
disease-causing mutations frequently induce significant remodelling of protein’s 
interactome. Therefore, my first objective was to compare interactomes of wild type 
ATP7B (ATP7B-WT) and of its most frequent H1069Q mutant (ATP7B-H1069Q). 
Considering that a large number of ATP7B interactions require Cu to occur (Lim et 
al., 2006), cell expressing ATP7B or its mutant were enrolled into proteomics study 
after exposure to Cu. I also took in account that ATP7B is expressed mainly in the 
liver (Bull et al., 1993; Kuo et al., 1997; Michalczyk et al., 2000) and thus used 
hepatic HepG2 cell line to detect ATP7B binding partners. 
To characterize ATP7B-WT and ATP7B-H1069Q interactomes I used an 
immunoprecipitation approach combined with mass spectrometry analysis, which was 
carried out in collaboration with the proteomics facility in CEINGE (Naples). 
Unfortunately, a hepatic cell line with endogenous expression of ATP7B-H1069Q 
mutant has yet to be developed. Therefore, I used GFP-tagged variant of ATP7B-
H1069Q in HepG2 cells and WT version of ATP7B with the same tag as a control. To 
this end HepG2 cells were transduced with adenoviruses carrying either ATP7B-WT 
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(Ad-ATP7B-WT) or ATP7B-H1069Q (Ad-ATP7B-H1069Q). Protein complexes in 
transduced cells were allowed to form and the proteins of interest were 
immunoprecipitated from cell extracts with anti-GFP antibody. The 
immunoprecipitated material containing the ATP7B bait and its binding partners were 
then fractionated by SDS-PAGE and the individual protein components were 
identified by mass spectrometry. Analysis of the interactome revealed that WT 
protein and mutant have a large cohort of 52 common binding partners (Fig. 6A). The 
presence of the known ATP7B interactor glutaredoxin (Lim et al., 2006) among the 
pulled-down proteins confirmed the specificity of the IP approach.  However, both 
ATP7B variants exhibited specific interactions (31 for WT protein and 51 for the 
mutant), indicating that H1069Q mutation remodels ATP7B interactome (Fig. 6A; see 
supplementary data).  
Gene Ontology (GO) analysis indicated that the group of mutant-specific interactors 
exhibited significant enrichments in such categories as “unfolded protein binding”, 
“protein folding” and “protein stabilization” (Fig. 6C). In contrast WT protein 
interactome exhibited enrichments in proteins that belong to membrane trafficking 
and cell adhesion groups (Fig. 6B). Apparently, differences in the interactomes of 
ATP7B-WT and ATP7B-H1069Q indicated the consequences of the mislocalisation 
of the mutant ATP7B-H1069Q to the ER, such as enhanced interactions with the 
components of the ER-associated quality control and degradation (ERAD) 
machineries. So, it is possible that ATP7B-H1069Q expression modulates ER quality 
control mechanisms and accelerates the degradation of the protein, as reported 
previously (Chesi et al., 2016; de Bie et al., 2007).	 
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Fig. 6: Proteomics reveals strong differences in ATP7B-WT and ATP7B-H1069Q interactomes. 
 
Putative interactors of ATP7B-WT and ATP7B-H1069Q were identified using a standard proteomics approach 
(see Methods).  The diagram in panel A shows the number of interactors that were specific for ATP7B-WT or for 
ATP7B-H1069Q as well as the number of common interactors. GO analysis revealed ATP7B-WT interactors to be 
enriched in proteins belonging to membrane trafficking categories, while mutant-specific interactors were enriched 
in proteins involved in ER‐associated protein quality control and degradation. Panel B shows the enriched GO 
Biological Process Categories for ATP7B-WT interactors based on their p value. Red bars indicate membrane 
trafficking categories. Panel C shows the enriched GO Biological Process Categories for mutant interactors. In 
contrast to ATP7B-WT interactors, GO reveals that mutant interactome is enriched in protein folding, unfolding 
protein binding and protein stabilization classes (red bars). 
 
Interestingly, the well-known ΔF508 mutant of CFTR exhibits the similar trend in 
interactome remodelling towards increase of ER quality control component binding 
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(Young, 2014) indicating that disease-causing mutations significantly affect the 
binding landscape of these complex transmembrane proteins. 
 
3.1.2 SILAC proteomics analysis confirmed the differences between ATP7B-WT 
and ATP7B-H1069Q interactomes  
Apart from the specific binding partners WT and H1069Q forms of ATP7B exhibited 
common component in their interactomes. Several proteins from this common group 
(DNAJB1, ERLIN1, PSMA1 to name few) belong to ER proteostatic machinery and 
thus could be involved in quality control of WT ATP7B and of its mutant. 
Unfortunately, traditional proteomics approach does not allow evaluation of  
quantitative difference in these common proteins binding to ATP7B-WT or ATP7B-
H1069Q. Thus, to detect these differences I decided to use a very sensitive proteomics 
approach, SILAC analysis (Fig. 7). SILAC is a straightforward metabolic labelling 
technique used for mass spectrometric (MS)-based quantitative proteomics. It allows 
the identification and quantitation of thousands of proteins in a single experiment 
(Ong et al., 2002). In this approach, samples under comparison are differentially 
labelled and then mixed prior to analysis by nano-LC-MSMS. To detect the molecules 
that may interact with ATP7B, I used in my experiments cells expressing GFP as a 
negative control, and compared interactomes of ATP7B-WT and ATP7B-H1069Q in 
HepG2 cells (Fig. 8; see also Supplementary data ). 
 
 
49	
 
 
 
 
 
 
 
 
 
 
The cells were loaded with amino acid isotopes of different weight. Then the protein 
complexes were allowed to form and the cell extracts immunoprecipitated with α-
GFP antibody. The immunoprecipitated material containing the ATP7B bait and its 
binding partners was then fractionated by SDS-PAGE and the individual protein 
components were identified by mass spectrometry (See the supplementary table with 
SILAC results in supplemental data).  
This approach allowed me to identify interactions of ATP7B that are affected by the 
H1069Q mutation in the ATP7B gene, and potentially cause retention of the mutant 
	
Fig. 7: SILAC analysis. 
HepG2 cells were preloaded 
with light (K0R0), medium 
(K4R6) and heavy (K8R10) 
isotopes if lysine and arginine. 
Then light, medium and heavy 
cells were infected with 
adenovirus carrying GFP 
alone, ATP7B-WT-GFP or 
ATP7B-H1069Q-GFP 
respectively and treated 
treated with CuSO4 200 µM . 
Anti-GFP antibody was 
utilized to immunoprecipitate 
GFP-tagged ATP7B and 
control GFP from total cell 
lysates. Interactors were 
identified using spectrometry 
and bioinformatics analysis. 	
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within the ER. I evaluated the strength of interaction in SILAC experiments and 
found that although some interactors bind both WT  and mutant proteins proteins 
exhibit preference for one of the ATP7B variants (determined from herein as “WT-
specific” and “mutant-specific” as well). As in the case of traditional proteomics GO 
analysis revealed strong enrichment of mutant interactome in categories that were 
associated to protein unfolding, such as “chaperone binding”, “unfolded protein 
binding”, and “response to unfolded protein”. (Fig. 8). In particular we noted “HSP70 
protein binding” and “regulation of cell response to heat” enrichments that suggest 
preferential interaction of the mutant with a subset of HSP70-associated 
chaperones/proteins. Interactome of ATP7B-WT also contained several components 
of proteostatic machinery (mainly associated to proteasome regulation) but did not 
exhibit specific enrichments in unfolded protein terms. This indicates that the mutant 
is retained in the ER with specific subset of quality control proteins, which could be 
targeted to circumvent ER accumulation and degradation of ATP7B-H1069Q. 
To prioritize interactors that could be targeted for mutant correction I considered the 
interaction score of each binding partner. This parameter reflects the strength of the 
interaction and takes in account peptides detected with SILAC and the percentage of 
protein sequence coverage by these peptides. The interactors with higher score in both 
categories were considered as the straightforward candidates for validation in further 
ATP7B trafficking experiments. In addition to above approaches, each putative 
interactor of either ATP7B, or ATP7B-H1069Q or both were evaluated for its 
relevance for membrane trafficking and ER quality control.  
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Fig. 8: SILAC Analysis  reveals differences  in ATP7B-WT and ATP7B-H1069Q interactomes. (A) Putative 
interactors of ATP7B-WT and ATP7B-H1069Q were identified using SILAC proteomics approach.  The diagram shows 
the number of interactors that were specific for ATP7B-WT or for ATP7B-H1069Q as well as the number of common 
interactors. (B-C) . Panel B and C show the GO biological process categories enriched in ATP7B-WT and ATP7B-
H1069Q interactomes respectively. Protein quality control categories are indicated in red. In contrast to ATP7B-WT 
interactors, GO analysis revealed enrichment of ATP7B-H1069Q interactome in chaperone binding, unfolded protein 
binding protein folding, response to unfolded protein, regulation of cellular response to heat, HSP70 protein binding 
classes as revealed by red bars. 
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3.2. Inhibition of HSP70 rescues trafficking of the ATP7B-H1069Q 
 
3.2.1. Selection of HSP70 as a target for ATP7B-H1069Q mutant correction 
Among different specific interactors of the ATP7B mutant, HSP70, looked 
particularly interesting for three different reasons. HSP70 exhibited particularly high 
score as 27 peptides that cover 43% of its sequence were detected in ATP7B 
pulldowns. SILAC proteomics indicated almost 2.5 fold increase in HSP70 binding to 
mutant compared ATP7B-WT. GO analysis of mutant interactome revealed specific 
enrichment in HSP70 binding proteins. Finally, a recent study from our lab suggests 
that p38 and JNK stress kinases upregulate HSP70 to accelerate ER degradation of 
ATP7B-H1069Q mutant (Concilli et al., 2016). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9. Mechanisms of HSP70-mediated folding/degradation pathways. CFTR follows chaperone-mediated 
pathways for degradation (top) as well as folding (bottom). In the folding pathway, starting from the left, DNAJA1 
(red) activates the binding of HSC/HSP70 (yellow) to CFTR to initiate folding; co-chaperone HOP (light green) 
transfers CFTR from HSC/HSP70 to HSP90 (purple) and its co-chaperones (dark green) to complete folding and 
allow trafficking to the cell surface. In the degradation pathway, the HSC/HSP70 co-chaperone CHIP (orange) is 
an E3 ubiquitin ligase that promotes degradation of misfolded CFTR. CHIP functions in parallel to membrane-
anchored E3 ubiquitin ligases gp78 and RMA1 and associated components (brown), which do not depend on 
HSC/HSP70. The DNAJ co-chaperones (red) CSPα and DNAJB12 promote CFTR degradation by CHIP, and by 
gp78 and RMA1, respectively. The NEFs (blue) BAG2, BAG1 and HSPBP1 interfere with CHIP activity, BAG1 
by causing HSC/HSP70 to release substrate, BAG2 and HSPBP1 by binding directly to CHIP. The NEF HSP110 
also promotes CFTR degradation. HSP110 is homologous to HSC/HSP70 in the ATP-bound state.  
Adapted from Young et al., 2014 
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HSP70 is a chaperone that plays a 
key role in proteostasis of wide range 
of proteins via regulating their 
folding/degradation (Bukau et al., 
2006; Frydman, 2001; Hartl et al., 
2011; Mayer and Bukau, 2005). 
Excessive association of HSP70 with ATP7B mutant could reflect a so called 
“chaperone trap” of misfolded membrane protein in the ER that usually activates 
degradation of the aberrant protein product. Such a chaperone trap and its 
involvement in ΔF508 mutant of CFTR has been well documented (Coppinger et al., 
2012; Young, 2014)  (Fig. 9). Thus I reasoned that HSP70 could be explored as a 
target for ATP7B mutant correction. Hsp70 plays a key role in ER-associated quality 
control of the transmembrane proteins. The available literature indicates that it may 
target misfolded proteins to ERAD or facilitate their folding and sorting into the 
secretory pathway. This depends on the degree of protein misfolding and other 
chaperons that cooperate with Hsp70 (Young, 2014). The scheme in Fig. 9 illustrates 
how HSP70 drives either folding or degradation of CFTR. So it is tempting to 
speculate that HSP70 could deal in the same way with ATP7B mutant. 
Interestingly, SILAC proteomics data suggest that ATP7B-H1069Q exhibits stronger 
interaction with HSP70 partners such DNAJs and BAG1 (Fig. 10) that promote 
degradation of misfolded proteins (Young, 2014). This suggests that HSP70 is likely 
to direct the mutant to degradation rather than to folding pathway. Indeed, SILAC 
	
Fig. 10. ATP7B-H1069Q interactome contains the 
components of HSP70-mediated degradation pathway.	
54	
experiments indicate reduced ATP7B-H1069Q binding to HSP90, which cooperates 
with HSP70 in the process of protein folding. 
 
3.2.2. HSP70 silencing corrects ATP7B-H1069Q localization  
As outlined in the introduction, ATP7B-WT resided within the TGN  (labelled by 
TGN46) at low Cu conditions and moved to the post-Golgi endo-lysosomal vesicles 
and cell surface upon exposure to Cu (Fig. 11A). In contrast, significant amounts of 
ATP7B-H1069Q remained in the ER independently of the Cu concentrations (Fig. 
11B). To determine whether inactivation of HSP70 facilitates ATP7B-H1069Q export 
from the ER, I decided to suppress HSP70 using RNAi in HeLa and HepG2 cells. 
HepG2 cells were used as WD-relevant type, while HeLa cells were added because 
usually siRNA-mediated silencing works very efficiently in this cell type. The cells 
were incubated with HSP70-specific siRNAs and subsequently transduced with Ad-
ATP7B-H1069Q to express the mutant. Then the cells were fixed and the intracellular 
distribution of ATP7B-H1069Q in HSP70-silenced cells was compared to cells 
incubated with control siRNAs (siControl). Given that ATP7B-H1069Q exhibited 
similar ER distribution at both low and high Cu levels, we did not modulate Cu levels 
and analysed pattern of ATP7B mutant in both control and silenced cells at steady 
state conditions. 
Ablation of HSP70 caused a remarkable impact on the ATP7B-H1069Q localisation, 
as its amounts within the ER were strongly reduced (Fig. 12A). Instead of the ER, 
ATP7B mutant was observed in the perinuclear Golgi area and to some extent within 
post-Golgi LE/lysosome like structures (Fig. 12A, arrows) in HSP70-deficient cells. 
Western blot revealed efficient silencing of HSP70 in both HeLa and HepG2 cells,  
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Fig. 11. Trafficking of ATP7B-WT and ATP7B-H1069Q under low and high copper condition. HepG2 cells expressing 
GFP-tagged version of ATP7B-WT (A) or ATP7B-H1069Q (B) were treated with Cu chelator BCS (200 µM overnight) or 
CuSO4 (200 µM for 2h) fixed and stained with ER marker VAP-A, Golgi marker TGN46 and late endosome (LE)/lysosome 
marker LAMP1. Confocal microscopy revealed that ATP7B-WT moved from the Golgi (A, top row) to the cell surface (A, 
bottom row) and LE/lysosome structures (arrows in A). Most of ATP7B-H1069Q remained within the ER independently 
from Cu depletion (B, top row) or Cu supply (B, bottom row). Arrows in panel B indicate overlap of ATP7B-H1069Q with 
VAP-A in the ER. Scale bar for panels A and B = 4.5 µm. Experiment was done in triplicate. Mean ±SD. 	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
although in contrast to my expectation siRNA better suppressed HSP70 expression in 
HepG2 cells than in HeLa cells (Fig. 12B). This could explain why in HepG2 line the 
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percentage of cells with ATP7B-H1069Q in the ER was stronger impacted upon 
HSP70 ablation (Fig. 12C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 12. HSP70 silencing reduces retention of ATP7B-H1069Q in the ER. 
HeLa or HepG2 cells expressing GFP-tagged ATP7B-H1069Q were treated with control (siControl) or HSP70-
specific (siHSP70) siRNAs and further processed for confocal microscopy (A, C) or Western blot (B). (A) 
Confocal microscopy revealed that HSP70 silencing reduces amount of ATP7B- H1069Q within the ER and 
promotes the mutant trafficking to the Golgi and LE/lysosome-like post-Golgi structures (arrows). Scale bar for 
panel A = 4.7 µm. (B) Western blot shows reduction of HSP70 expression in both HeLa and HepG2 cells. (C) 
Morphometric analysis confirms that HSP70 depletion decreases the percentage of the cells exhibiting ATP7B-
H1069Q mutant within the ER (n= 10 fields). * - p<0.05 (t-test). Experiment was done in triplicate. Mean ±SD. 
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Fig. 13. HSP70 depletion attenuates 
degradation of ATP7B-H1069Q. 
HepG2 cells expressing GFP-tagged 
ATP7B-H1069Q were treated with 
control (siControl) or HSP70-specific 
(siHSP70) siRNAs and further 
processed for Western blot to reveal 
ATP7B mutant with anti-GFP antibody. 
Western blot shows increase in the 
levels of ATP7B-H1069Q expression in 
cells treated with HSP70-specific 
siRNAs indicating reduced degradation 
of the mutant. The graph shows the 
changes in ATP7B mutant. Experiment 
was done in triplicate.  	
This indicates that suppression of HSP70 facilitates export of ATP7B mutant from the 
ER into distal compartments of secretory pathway, where ATP7B normally resides 
and functions. Thus, HSP70 could be explored as a potential target for correction of 
the most frequent Wilson disease-causing mutant. 
 
 
 
 
 
 
 
 
 
Faster export of ATP7B-H1069Q from the ER in HSP70-depleated cells may reduce 
exposure of the mutant to the protein quality surveillance and, hence, inhibit the 
mutant degradation. Thus, I decided to check whether HSP70 suppression also has an 
impact on H1069Q turnover. To this end I performed WB experiment in which HeLa 
cells infected with Ad-ATP7B-H1069Q were treated with either control or HSP70-
specific siRNAs. I found that the level of ATP7B-H1069Q signal was higher in 
HSP70-silenced cells compared to the control (Fig. 13). This observation suggests 
that HSP70 is involved in the degradation of the mutant and that suppression of 
HSP70 attenuates the degradation process. 
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3.2.3. H1069Q mutation increases ATP7B interaction with HSP70  
HSP70 interacts with wide range of proteins (Young, 2014) and frequently appears as 
a false positive interactor in proteomics studies. Thus, in order to confirm and 
characterize in detail the interaction between HSP70 and ATP7B, I performed a CoIP 
experiment in HepG2 cells expressing WT and H1069Q ATP7B variants. I observed 
considerably higher amounts of HSP70 in ATP7B-H1069Q pull downs when 
compared to WT protein (Fig. 14). This indicates stronger interaction of the mutant  
 
 
 
 
 
 
Fig. 14. ATP7B-H1069Q exhibits stronger interaction with HSP70. 
GFP-tagged ATP7B-WT or ATP7B-H1069Q were expressed in HepG2 cells. Then ATP7B-GFP was 
immunoprecipated from cell lysate. Western blot (A) shows higher levels of HSP70 in ATP7B-H1069Q pulldowns 
indicating stronger interaction of the mutant with HSP70. Notably, the level of HSP70 signal was also higher in 
total lysates from cells expressing ATP7B-H1069Q protein than from cells expressing WT protein.  The graph (B) 
shows normalized level of HSP70 bound either WT protein or H1069Q mutant. Experiment was done in triplicate. 
 
with HSP70. Interestingly, overall levels of HSP70 expression were higher in total 
lysates of cells expressing ATP7B mutant than in cells expressing WT protein. This 
can be expected because recent study from our lab suggests that the presence of 
ATP7B-H1069Q mutant activates p38- and JNK-driven stress response pathways 
(Chesi et al., 2016), which in turn upregulate a cluster of ER quality control genes 
comprising HSP70 (Concilli et al., 2016). However, the magnitude of ATP7B-
H1060Q interaction with HSP70 could not be exclusively explained by increased 
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Fig. 15. Proximity ligation assay 
(PLA) reveals stronger 
association of HSP70 with 
ATP7B mutant.  HepG2 cells 
were infected with adenoviruses 
carrying GFP-tagged ATP7B-WT 
or ATP7B-H1069Q, treated with 
Cu and processed for PLA analysis. 
(A) Efficiency of PLA assay was 
confirmed by presence of the PLA 
signal (red spots) between ATP7B 
variants and p62 (DNCT4), a well-
known interactor of ATP7B. (B) 
ATP7B proteins did not generate 
PLA signal with TfR (employed as 
a negative control). (C) ATP7B-
H1069Q induced stronger PLA 
signal with HSP70 in comparison 
to WT protein, indicating that 
HSP70 exhibits higher affinity for 
the mutant protein. Scale bars = 
5µm (A-C) Experiment was done 
in triplicate. 	
HSP70 levels in mutant-expressing cells. It seems that HSP70 only moderately rise in 
total lysates upon mutant expression, while amount of HSP70 in ATP7B-H1069Q 
pull down exhibit several fold increase. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To confirm the interaction using complementary approach I utilized proximity 
ligation assay (PLA). In this way protein association within 40nm range from each 
other can be detected (Soderberg et al., 2006). The strength of such association could 
be evaluated on the basis of the presence of red fluorescent spots that indicate 
interaction. The HepG2 cells were infected with Ad-ATP7B-WT or Ad-ATP7B-
H1069Q and processed for PLA analysis. First I used positive control and found that 
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both ATP7B variants generates PLA signal with well-known ATP7B  interactor p62 
(DNCT4) (Fig. 15A). In contrast I did not obtain (as expected) the PLA signal 
between ATP7B proteins and Transferrin Receptor (TfR), which was used as a 
negative control (Fig. 15B). Finally I found that the ATP7B-H1069Q induces stronger 
PLA staining with HSP70 than WT protein (Fig. 15C), indicating that HSP70 binds 
preferentially the mutant protein, as in the case of co-IP experiments and SILAC 
proteomics data. 
 
3.2.4. Chemical inhibitor of HSP70 rescues ATP7B-H1069Q localization and 
stability 
To test further the potential of HSP70 as a target for correction of ATP7B-H1069Q 
mutant I thought to suppress HSP70 with a different approach. Over the last decade 
several chemical compounds that inhibit HSP70 were reported (Kim et al., 2014; 
Prota et al., 2012; Yu et al., 2010). In 2014 Howe et al. published a paper, in which 
they found a small molecule inhibitor of HSP70 called HS-72 (Fig. 16). This  
 
 
 
 
 
Adapted from Howe et al. 2014  
Fig. 16: HSP70 inhibitor HS-72.                       
Panel A depicts chemical structure of HSP70 inhibitor HS-72. Panel B shows 2D and 3D structures of ATP7B. 
Arrow indicated putative binding site of HS-72 at C306 position.	
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molecule acts as an allosteric inhibitor reducing ATP binding in the ATPase domain of 
the HSP70 protein. Moreover, the authors demonstrated very high specificity of the 
inhibitor for HSP70 and lack of any significant impact on other similar chaperones. 
Apparently, this inhibitor binds to HSP70 at the C306 residue, which is not shared by 
other Hsp70 family members such as Hsc70, Grp78, and Grp75, and Hsp90 (Howe et 
al., 2014).  
Fig. 17. HSP70 inhibitor reduces 
retention of ATP7B-H1069Q in the 
ER. 
HepG2 cells expressing GFP-tagged 
ATP7B-H1069Q were treated with 
10 µM HSP70-specific inhibitor HS-
72 for 24 hours and further processed 
for confocal microscopy. (A) 
Confocal microscopy revealed that 
HS-72 reduces the amount of 
ATP7B- H1069Q within the ER and 
promotes the mutant trafficking to 
the Golgi and LE/lysosome-like post-
Golgi structures (arrows). Scale bars 
for panel A= 4 µm (B) Morphometric 
analysis confirms that HSP70 
suppression with HS-72 decreases 
the percentage of cells exhibiting 
ATP7B-H1069Q mutant within the 
ER (n= 10 fields). * - p<0.05 (t-test).  
Experiment was done in triplicate. 
Mean ±SD. 
 
I took advantage of this inhibitor and treated cells to test whether suppression of 
HSP70 with specific chemical compound leads to correction of ATP7B-H1069Q in 
terms of localization and stability of the protein product. First I checked whether the 
inhibitor rescues ATP7B localization. When I stained HS-72-treated cells with marker 
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of Golgi (TGN46) or lysosomes (LAMP1) at the steady state conditions, I found the 
mutant in both Golgi and to some extent in post-Golgi Lamp1-positive structures 
while in control cells it was mainly distributed over the ER (Fig. 17A). Morphometric 
analysis confirmed that HS-72 significantly reduced the proportion of cells that 
contained ATP7B-H1069Q in the ER (Fig. 17B). Thus, this HSP70 inhibitor seems to 
be quite effective in mutant rescue from the ER to the compartments where ATP7B 
normally works. 
Then, I tested whether HS-72 reduces ATP7B-H1069Q degradation (Fig. 18). 
Immunoblotting experiment revealed that exposure to different concentrations of 
HSP70 inhibitor increased expression levels of ATP7B mutant in HeLa cells 
indicating that suppression of HSP70 reduces degradation of ATP7B-H1069Q. 
Similar experiments were also performed in WD-relevant hepatic cell line HepG2. As 
in HeLa cells, HS-72 treatment increased stability of ATP7B mutant although higher 
concentrations of inhibitor were required to prevent degradation in HepG2 cells (Fig. 
18A). This prompted me to investigate the impact of HS-72 on ATP7B-H1069Q 
stability using complimentary approach. 
At the ER level, all newly synthetized proteins undergo folding, to be then delivered 
to their final destinations through the appropriate membrane-trafficking routes. The 
failure of a protein to pass the quality-control monitoring directs the mis-folded 
protein to degradation (Chakrabarti et al., 2011). The kinetics of the degradation 
process can be easily investigated using cycloheximide, an eukaryote protein 
synthesis inhibitor. Cycloheximide treatment helps to understand whether a given 
protein remains stable over time or undergoes rapid turnover (Buchanan et al., 2016). 
Several studies reported that the half-life of ATP7B-H1069Q protein product is 
shorter than the half-life of ATP7B-WT and usually ranges between 30 minutes and 1  
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Fig. 18. HSP70 inhibitor attenuates degradation of ATP7B-H1069Q.  (A) HeLa and HepG2 cells expressing 
ATP7B-H1069Q were treated with different concentrations of HS-72 inhibitor for 24 h. Western blots show an 
increase in ATP7B-H1069Q levels mutant protein in cells treated with HS-72 inhibitor in contrast to control cells. 
The graph shows the changes in ATP7B mutant.(B) HepG2 cells expressing ATP7B-H1069Q were treated with 10 
µM HS-72 for 24 h or kept untreated before incubation with cycloheximide (CHX) for either 30 minutes or 5 
hours. Western blot indicates that the treatment with HS-72 slowed down dynamics of CHX-induced decay of 
ATP7B mutant protein. The graph shows the changes of the mutant over the time. Experiment was done in 
triplicate. 
 
hour and half (Payne et al., 1998). Thus, in order to see if HSP70 inhibitor reduces 
degradation of ATP7B mutant, I treated HepG2 cells expressing ATP7B-H1069Q with 
HS-72 and blocked protein biosynthesis with cycloheximide (CHX) for two different 
time intervals: 30 min and 5 hours. Western blot revealed that HS-72 increased 
amounts of ATP7B mutant at both 30min and 5h intervals of CHX treatment (Fig. 
18B) indicating that HSP70 inhibitor slows down the mutant degradation. 
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Thus, taken together, these observations suggest that the suppression of HSP70 allows 
the most frequent Wilson disease ATP7B-H1069Q mutant to overcome ER retention, 
probably escaping the HSP70-dependent ER quality control mechanisms.  
 
3.2.5. HSP70 inhibitor facilitates ATP7B-H1069Q trafficking to the appropriate 
cell-surface domain in hepatic cells 
Considering that suppression of HSP70 with either RNAi or chemical inhibitor 
produced almost identical impact on ATP7B-H1069Q stability/localization, I utilized 
HS-72 as a simpler tool to inhibit HSP70 in further experiments. The first series of 
such experiments was designed to understand to what extent HSP70 suppression 
facilitates delivery of ATP7B-H1069Q to the Cu excretion sites. 
To support excretion of Cu into the bile, ATP7B has to be delivered towards the 
canalicular (called also apical or biliary) area of hepatocytes (Nyasae et al., 2014). 
Biliary flow in turn eliminates excess Cu from the body preventing reabsorption of 
the metal in the intestine (Linder et al., 1998). The failure of ATP7B to reach this 
specific domain of the hepatocyte membrane results in Cu accumulation in the liver 
and the further developments of the main symptoms of Wilson disease. Targeting of 
ATP7B to the canalicular surface of hepatocyte relies on the N-terminal 9 amino acid 
37FAFDNVGYE45 stretch (Braiterman et al., 2009). Wilson disease-causing N41S 
mutation in this region severely impairs ATP7B targeting to the canalicular surface 
(Braiterman et al., 2009). In contrast, this N-terminal signal of ATP7B should not be 
affected by H1069Q mutation and should allow the mutant to reach canalicular area 
once the mutant would be able to leave ER. In this context, I tried to understand  
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Fig. 19. HSP-70 inhibitor facilitates delivery of ATP7B-H1069Q to canalicular domain of polarized hepatic 
cells.  
Polarized HepG2 expressing either WT (A) or H1069Q (B, C) were exposed to CuSO4 for 4h and stained with 
canalicular marker MRP2 and nuclear marker DAPI. HS-72 was added to the some wells with ATP7B-H1069Q 
expressing cells before exposure to Cu. Arrows in all images indicate MRP2-positive canalicular vacuole (cyst), 
which received ATP7B-WT (A), while mutant failed to reach canalicular area (B). HS-72 treatment induced 
ATP7B-H1069Q trafficking to canalicular surface (C). Panel D shows intensities of ATP7B (green) and MRP2 
(red) signals along the lines 1, 2, and 3 drawn through the canalicular vacuole in panels A, B and C respectively. 
Peaks of ATP7B and MRP signals coincided in the case of WT (1) and mutant proteins exposed to HS-72 (3), 
while ATP7B signal did not exhibit any increase in MRP-positive canalicular area of untreated cells expressing 
H1069Q mutant. Scale bars for panels A-C = 4.8 µm (A-C). Experiment was done in triplicate.. 
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whether the ATP7B-H1069Q recovered from the ER by HSP70 inhibitor arrives at 
the biliary surface of hepatic cells.  
To determine whether this is the case, I grew the HepG2 cells under conditions that 
allow them to achieve maximal polarisation and to develop the apical canalicular 
cysts (also known as biliary cysts) (Treyer and Musch, 2013). Thus, these polarised 
HepG2 cells were exposed to Cu to trigger ATP7B transport, and then stained for 
MRP2 to reveal the apical (biliary) surface. Fig. 19A shows that exposure to Cu 
resulted in efficient delivery of ATP7B-WT to the canalicular domain of the cells. In 
contrast, no ATP7B-H1069Q was detected at the canalicular surface of these HepG2 
cells, even when Cu was added to the medium at high concentrations (Fig. 19B). 
However, exposure of these cells to HS-72 inhibitor resulted in an increase of the 
amounts of ATP7B-H1069Q in the canalicular region (Fig. 19C). This suggests that 
HS-72 facilitates mutant delivery of the mutant to the main Cu excretion site at the 
biliary surface of hepatic cells. Quantification (in Fig. 19D) confirmed this conclusion 
and revealed coincidence ATP7B and MRP2 fluorescence picks in the case of WT 
protein and of H1069Q mutant in HS-72-treated cells. In contrast, untreated cells 
expressing the mutant did not exhibit any increase in the ATP7B signal within MRP2-
positive area (Fig. 19D). 
Thus, once HS-72 inhibitor promotes the release of ATP7B-H1069Q from the ER, the 
ATP7B-H1069Q shows correct targeting to the biliary domain of the cell surface, 
where the Cu excretion occurs.  
67	
3.2.6. HSP70 inhibitor promotes delivery of ATP7B-H1069Q to plasma 
membrane  
Ability to drive Cu excretion from the cells constitutes the main homeostatic function 
of ATP7B (Lutsenko, 2010). A recent study from our lab shows that in response to 
increasing Cu ATP7B traffics from the TGN to endo-lysosomal organelles, where 
ATP7B sequesters Cu into lysosome lumen and stimulates exocytosis of such Cu-
loaded lysosomes. As a result of this exocytic process cells release excess Cu from 
internal storage compartments and deliver ATP7B to the cell surface, where ATP7B 
can directly pump toxic metal away from the cytosol across the plasma membrane 
(Polishchuk et al., 2014). Cu-dependent delivery of ATP7B to the cell surface was 
successfully investigated by surface biotinylation in a number of cell types 
(Polishchuk et al., 2014; van den Berghe et al., 2009). Thus, we employed this 
method in HeLa cells to test whether HSP70 suppression increases ATP7B-H1069Q 
mutant trafficking to the plasma membrane. 
 
 
 
 
 
 
Fig. 20.  HSP70 inhibitor stimulates ATP7B-H1069Q delivery to the cell surface. 
HeLa cells were infected with adenovirus carrying ATP7B-WT or ATP7B-H1069Q, treated with 10 µM HS-72 
inhibitor for 24 h and then with 200µM CuSO4 for 2 hours. Subsequently the cells were processed for cell surface 
biotinylation. (A) Western Blot shows that the treatment with HS-72 results in appearance of ATP7B-H1069Q in 
biotinylated fraction indicating partial correction of the mutant to the plasma membrane. (B) The graph shows 
normalized levels of ATP7B at the cell surface. Experiment was done in triplicate. 
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I found that ATP7B-WT was abundantly expressed at the cell surface, while ATP7B-
H1069Q was missing at the plasma membrane (Fig. 20) likely due to retention and 
degradation in the ER. Indeed, amount of ATP7B mutant in total cells lysates was 
significantly lower when compared to WT protein. Incubation with HS-72 
significantly increased overall amounts of ATP7B-H1069Q and resulted in increase of 
the mutant protein in cell surface biotinylated fraction (Fig. 20), demonstrating that 
the inhibition of HSP70 improves delivery of mutant to the plasma membrane where 
ATP7B usually operates in Cu excretion. 
	
3. 3. Search for FDA-approved correctors of ATP7B-H1069Q 
3.3.1. Identification of FDA-approved drugs with structure similar to HSP-70 
inhibitor  
Several lines of evidence (see above) suggest that HSP70 represents an attractive 
target for correction of ATP7B mutant. However, HSP70 is known to be involved in 
wide range of vitally important processes such as cellular prevention of protein 
aggregation, protein folding, trasport and regulation of proteins and others (Bukau et 
al., 2006; Frydman, 2001; Hartl et al., 2011; Kettern et al., 2010; Mayer and Bukau, 
2005; Pratt and Toft, 2003; Tyedmers et al., 2010). It also plays a key role in ER-
associated quality control of the numerous transmembrane proteins (Young, 2014). 
For this reason it would be risky to completely suppress HSP70 activity in patients 
with ATP7B-H1069Q mutation. On the other hand, it would be important to explore 
the potential of HSP70 inhibition for ATP7B mutant correction. Thus any eventual 
therapeutic strategy would require modulating the activity of HSP70 in a safe manner. 
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How might this objective be achieved? I had an idea to look for FDA approved drugs 
that could modulate HSP70 activity. FDA approved drugs are safe for patients as their 
toxicity has already been tested in clinical trials. I reasoned that some FDA approved 
drugs could be similar in terms of chemical structure to HS-72 and hence reduce the 
activity of HSP70, while other compounds may reduce expression of HSP70 protein 
product. Therefore, I decided to use two strategies for detection of FDA-approved 
drugs that could impact on HSP70. Firstly, I tried to find compounds whose structure 
resembles HSP70 inhibitor. Secondly, I attempted to detect FDA approved drugs that 
could modulate the expression of HSP70 protein.  
 
Fig. 21. FDA approved drugs exhibiting structural similarity to allosteric HSP70 inhibitor. 
HS-72 was used as query structure for 3D ligand-based screening of a collection of FDA-approved drugs. 
Structural similarity score was calculated Molecular Interaction Fields (MIFs) overlapping of the query structure 
with 1309 FDA-approved drugs. Three hits were retrieved with a structural similarity score more than 0.5 to HS-
72 inhibitor (Nialamide, Domperidone and Gavestinel). 
 
The TIGEM Bioinformatic Core found three different FDA approved drugs using HS-
72 (Howe et al., 2014) as a query structure for 3D ligand-based screening of a 
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collection of FDA-approved drugs. Structural similarity score of each compound was 
calculated on the basis of Molecular Interaction Fields (MIFs) overlapping of the 
query structure with 1309 FDA-approved drugs (Baroni et al., 2007). Three hits with 
a structural similarity score more than 0.5 (Carosati et al., 2004; Goodford, 1985) 
were retrieved: Nialamide, Domperidone and Gavestinel (Fig. 21). All 3 drugs were 
enrolled in further experiments to test their potential for ATP7B-H1069Q mutant 
correction. 
 
3.3.2. Domperidone treatment improves the trafficking of ATP7B-H1069Q and 
prevents its degradation 
Among 3 tested drugs, only Domperidone had a beneficial impact on ATP7B mutant, 
	
Fig. 22. Domperidone reduces 
degradation of ATP7B-H1069Q and 
its retention in the ER. 
HepG2 cells expressing GFP-tagged 
ATP7B-H1069Q were treated with 
domperidone for 24 h and further 
processed for western blot (A) or 
confocal microscopy (B). (A) Western 
blot shows that domperidone treatment 
increases ATP7B-H1069Q levels in a 
concentration-dependent manner. (B) 
Confocal microscopy revealed that 
domperidone treatment (10µM) reduces 
the amount of ATP7B-H1069Q within 
the ER and promotes the mutant 
trafficking to the Golgi. 
Scale bars= 4 µm 
 (C) Morphometric analysis confirms 
that domperidone decreases the 
percentage of cells exhibiting ATP7B-
H1069Q mutant within the ER (n=10 
fields). *** - p<0.001 (t-test).  	
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correcting its localization and inhibiting degradation, while others did not make 
significant impact on mutant function/localization. Domperidone is a peripherally 
selective antagonist of dopamine D₂ receptor, which is expressed mainly in brain 
(Champion et al., 1986; Sakano et al., 2016). This drug is normally used as an 
antiemetic, gastroprokinetic agent, and galactogogue (Leeser and Bateman, 1985; 
Ortiz et al., 2015; Robbins et al., 2016; Schey et al., 2016).	 
Western blot revealed that domperidone increases ATP7B-H1069Q levels in a 
concentration-dependent manner (Fig. 22A) probably protecting the mutant from 
degradation. In parallel, I treated HepG2 cells expressing the mutant with 
Domperidone to evaluate the impact of the drug on ATP7B-H1069Q localization. 
Domperidone-treated cells exhibit less mutant in the ER when compared to untreated 
cells, while ATP7B-H1069Q colocalization with the Golgi marker TGN46 improved 
(Fig. 22B). Morphometric analysis supported these observations and indicated very 
robust reduction in the number of cells retaining the ATP7B mutant in the ER (Fig. 
22C). Finally, I tested whether domperidone facilitates delivery of ATP7B-H1069Q 
mutant to the canalicular domain in polarized hepatic cells upon increase in Cu levels. 
Even upon stimulation with Cu ATP7B-H1069Q fails to reach MRP2-positive 
canalicular domains in polarized HepG2 cells as most of the protein remains within 
the ER (Fig. 23A). In contrast, Domperidone-mediated rescue of ATP7B mutant from 
the ER allowed ATP7B-H1069Q to be at least partially delivered to canalicular 
domain of HepG2 cells (Fig. 23B). 
In conclusion, our results together suggest that domperidone treatment improves 
ATP7B-H1069Q localization and significantly attenuates the mutant degradation. 
Importantly, domperidone is considered to be very safe drug as it is widely used 
against nausea and vomiting (Leeser and Bateman, 1985; Ortiz et al., 2015; Robbins 
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et al., 2016; Schey et al., 2016). Considering that large cohort of WD patients develop 
nausea and vomiting symptoms under standard treatment (Zn salts or Cu chelators), 
domperidone could be used straightforwardly in such patients and, thus, its beneficial 
impact on individuals with H1069Q mutation in ATP7B may be easily evaluated in 
clinical studies. In the case of positive outcome this FDA-approved drug could be 
rapidly repurposed for WD treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 23. Domperidone facilitates delivery of ATP7B-H1069Q to canalicular domains of polarized hepatic 
cells.	 
Polarized HepG2 expressing H1069Q were exposed to CuSO4 for 4h and stained with canalicular marker MRP2. 
Domperidone (10µM) was added to the same wells with ATP7B-H1069Q expressing cells before exposure to Cu. 
Arrows in all images indicate MRP2-positive canalicular vacuole (cyst). Panel A shows that the mutant is absent in 
the canalicular area and remain diffusively distributed over the ER. Domperidone treatment induced ATP7B-
H1069Q trafficking to the canalicular surface (arrows in B). Panel C shows intensities of ATP7B-H1069Q (green) 
and MRP2 (red) signals along the lines 1 and 2 drawn through the canalicular vacuole in panels A and B, 
respectively. ATP7B-H1069Q signal did not exhibit any increase in MRP-positive canalicular area of untreated 
cells (1), while the peaks of ATP7B-H1069Q and MRP signals coincided in the cells exposed to domperidone (2).  
Scale bars for panels A and B = 5 µm. Experiment was done in triplicate.  
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3.3.3 Bioinformatics search for FDA-approved drugs that rescue ATP7B mutant  
As outlined above, the second strategy for identification of safe ATP7B-H1069Q 
correctors consisted in bioinformatics screening for FDA-approved compounds that 
may inhibit HSP70 expression. It is important to note that I tried to select HSP70 
supressing compounds without serious impact on other chaperone HSP90. A growing 
body of evidences suggest that while HSP70 could direct ER-retained proteins (like 
Δ508F CFTR mutant) to either degradation or folding, HSP90 mainly acts as pro-
folding factor to stabilise mutant proteins (Young, 2014). Thus, HSP90 inactivation 
would be undesirable while attempting ATP7B mutant correction.  
Thus, to find FDA-approved drugs with potential for HSP70 suppression (having no 
impact on HSP90) TIGEM Bioinformatics Core made a search in available 
transcriptome databases (Lamb et al., 2006)(see also Methods).  
This bioinformatics search returned a list of about 200 candidates and I decided first 
to see whether top hits from the list inhibit HSP70 expression in HepG2 cells. Among 
top 24 compounds from the list only one, Doxorubicin, substantially (almost 2 fold) 
reduced HSP70 expression as revealed by western blot (Fig. 24). This compound is 
known for its antineoplastic activity and frequently used for cancer treatment (Batist 
et al., 2002; Carvalho et al., 2009; Guo et al., 2011; Keizer et al., 1990; Marina et al., 
2002; Meredith and Dass, 2016; Minotti et al., 2004; Ruggiero et al., 2013; Weekes et 
al., 2002). Doxorubicin intercalates between base pairs in the DNA helix, thereby 
preventing DNA replication and ultimately inhibiting protein synthesis (Meredith and 
Dass, 2016). This mechanism suppresses growth of tumor cells, but extended (in 
terms of time) use of Doxorubicin could induce serious toxicities in tissues and organs 
with rapid cell turnover. Thus, its use for WD cure is doubtful due to the possibility of 
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serious side effects. The lack of significant impact on HSP70 expression by majority 
of top candidates from bioinformatics 
 
Fig. 24. Impact of FDA approved drugs on HSP70 expression. 
Top FDA-approved drugs from bioinformatics study were supplied to HepG2 cells at 10µM concentration for 24 
h. Expression of HSP70 in treated cells was analysed using Western blot (A) and quantified using normalization to 
housekeeping protein GAPDH (B). Only Doxorubicin (shown in red) was capable of substantially reducing HSP 
expression. Experiment was done in triplicate. 
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searches prompted me to look for available literature data that would help to prioritize 
bioinformatics hits for ATP7B-H1069Q correction. I found that anti-inflammatory 
corticoids have been reported to correct to some extent stability and function of CFTR 
mutant (Pesce et al., 2016). Among the hits from bioinformatics search beclometasone 
belong to this family. Thus, I decided to evaluate potential of this drug as well as 
similar FDA-approved compounds (Momethasone and Dexamethasone) for ATP7B 
mutant rescue. 
 
3.3.4. FDA-approved glucocorticoid receptor agonists correct localization of 
ATP7B-H1069Q and reduce its degradation. 
Beclomethasone, Mometasone and Dexamethasone belong to a class of 
glucocorticoid receptor (GCR) agonists and are widely used as anti-inflammatory 
agents in skin disorders, allergic rhinitis, asthma, autoimmune diseases, etc. (Amar et 
al., 2016; Kim et al., 2017; Liu et al., 2017; Manguso et al., 2016; Orellana et al., 
2012; Podvigina et al., 2012; Singh et al., 2016; Ushkalova et al., 2016; Virkud et al., 
2017). To evaluate whether GCR agonists have any impact on ATP7B-H1069Q 
localization I treated mutant-expressing HepG2 cells with beclomethasone, 
mometasone and dexamethasone at different concentration and evaluated the degree 
of ATP7B re-location from the ER to distal compartments of the biosynthetic 
pathway. Fig. 25A shows that all three drugs reduced the amount of the mutant 
detectable in the ER and favoured trafficking of ATP7B-H1069Q to the Golgi and 
post-Golgi compartments. This observation was supported by morphometric analysis, 
which indicates significant reduction in the percentage of cells exhibiting ATP7B-
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H1069Q in the ER upon beclomethasone, mometasone and dexamethasone treatment 
(Fig. 25B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 25. FDA-approved GCR agonists reduce retention of ATP7B-H1069Q in the ER and its degradation. 
HepG2 cells expressing GFP-tagged ATP7B-H1069Q were treated with drugs as indicated in corresponding 
panels for 24 h and further processed for confocal microscopy (A) or Western blot (B). (A) Confocal microscopy 
shows reduced retention of ATP7B-H1069Q within the ER in cells treated with GCR agonists. Scale bar for panel 
A = 4.5 µm (B) Morphometric analysis confirms that FDA-approved drugs reduce the percentage of the cells, 
which contain ATP7B-H1069Q mutant within the ER (n= 10 fields). *** - p<0.001 (t-test). (C) Western blots 
indicates that Dexamethasone (15µM and 30µM), Mometasone (15µM and 30µM) and Beclomethasone (1µM and 
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10µM) increase the ATP7B-H1069Q levels. The graphs show changes in ATP7B mutant levels. Experiment was 
done in triplicate.  
 
In parallel, Western blot experiments revealed that GCR agonists increase amount of 
ATP7B mutant protein product in a concentration-dependent manner (Fig. 25C), 
indicating that these FDA approved compounds attenuate mutant degradation.  
It remains unclear how GCR agonists facilitate export of ATP7B-H1060Q from the 
ER and reduce degradation of the mutant. Fig. 25C indicates that neither drug caused  
a decrease in HSP70 levels. Instead, it seems that in the case of mometasone 
treatment HSP70 expression increases. Therefore, we tried to uncover the 
mechanisms through which beclomethasone, mometasone and dexamethasone rescue 
localization and stability of ATP7B-H1069Q. 
 
3.3.5. Impact of GCR agonists on ATP7B-H1069Q interaction with HSP70. 
Considering that GCR agonists do not seem to reduce HSP70 expression I 
hypothesised that the interaction of ATP7B-H1069Q with HSP70 could be altered by 
these drugs resulting in correction of the ATP7B mutant. In addition, I considered 
testing whether and to what extent HSP70 partner chaperones HSP90 and DNAJB1 
bind ATP7B-H1069Q in the presence of beclomethasone, mometasone and 
dexamethasone. As mentioned above, coupling of HSP70 with specific chaperones 
directs the fate of the misfolded transmembrane proteins to either degradation (as in 
the case of DNAJ proteins) or folding (as in the case of HSP90) (Young, 2014). It is 
also worth noting that both HSP90 and DNAJB1 were detected in ATP7B-WT and 
mutant interactomes (although the interaction score was not very high) and, hence, 
could modulate HSP70 activity on ATP7B-H1069Q. 
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To evaluate the impact of GCR agonists on ATP7B mutant interaction with 
chaperones, HepG2 cells were transduced with Ad-ATP7B-H1069Q and treated with 
Beclomethasone, Mometasone 
 
Fig. 26. Interaction of the ATP7B mutant HSP70 in GCR agonist-treated cells 
(A) HepG2 cells were infected with adenovirus carrying GFP-tagged ATP7B-H1069Q and treated with 
Dexamethasone, Mometasone and Beclomethasone. Then ATP7B mutant was immunoprecipated from the cell 
lysates.  1/10 of µg of total lysates and 10/10 µg of immunoprecipitates (IPs) were separated by SDS-PAGE and 
labelled with corresponding antibodies to reveal levels of ATP7B-H1069Q, HSP90, HSP70, DNAJB1 and 
GAPDH. (B) Quantification of the bands in IPs does not reveal significant changes in the ration between HSP70 
and ATP7B mutant. Experiment was done in triplicate. 
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and Dexamethasone. Then, ATP7B-H1069Q was immunoprecipitated from HepG2 
cell lysates and amounts of HSP70, HSP90 and DNAJB1 were revealed using specific 
antibodies in Western blots. Analysis of immunoprecipitates suggests that neither 
drug reduced HSP70 binding to the mutant (Fig. 26A). I noted that mometasone 
apparently increases HSP70 amounts in ATP7B mutant pull downs. However careful 
quantification of HSP70/ATP7B mutant ratio did not support this impression (Fig. 
26B). Importantly, both HSP90 and DNAJB1 were absent or barely detectable in 
immunoprecipitates although significant amounts of the proteins were revealed in cell 
lysates. Thus it seems that both chaperones do not bind to ATP7B mutant at 
significant levels and do not cooperate with HSP70 in regulation of ATP7B-H1069Q 
proteostasis. On the other hand, lack of impact on ATP7B-H1069Q/Hsp70 interaction 
suggests that GCR agonist do not necessarily act through HSP70 in the process of 
mutant correction. Although impact of these drugs on HSP70 activity cannot be 
entirely ruled out, it is likely that GRC agonist facilitate ATP7B-H1069Q trafficking 
through HSP70-independent mechanism. 
 
3.3.6. Drug-set enrichment Analysis (DSEA) suggests a possible molecular 
pathway of GCR agonist-mediated correction of ATP7B-H1069Q 
To understand the mechanisms behind rescue of ATP7B mutant by GCR agonists we 
employed bioinformatics analysis using DSEA (Drug-set Enrichment Analysis) tool 
(Napolitano et al., 2016). This computational method is based on drug-induced gene 
expression profiles and is able to identify the molecular pathways that are targeted by 
most of the drugs in the set. It has been already applied to identify the mechanisms of 
action shared by drugs known to be partially effective in rescuing CFTR mutant gene 
function in Cystic Fibrosis (Pesce et al., 2016). DSEA revealed that Momethasone, 
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Dexamethasone and Beclomethasone upregulate genes that belong to “Chaperone-
mediated protein transport” (GO:0072321) group. This pathway includes several 
genes: TIMM8B, TIMM8A, CLIP3, TIMM13, TIMM10, TIMM9, PEX19, TOR1A, 
HSPA8. Literature mining indicated that TIMM8B, TIMM8A, CLIP3, TIMM13, 
TIMM10, TIMM9 genes mainly operate in mitochondrial function (Lutz et al., 2003; 
Roesch et al., 2004) and could be hardly associated with ATP7B proteostasis. Instead 
HSPA8 is a cytosolic chaperone (member of the HSP70 protein family), which plays a 
role in ERAD (Matsumura et al., 2013). Therefore, HSPA8 emerges as a possible 
component of regulation of ATP7B mutant degradation. 
In order to evaluate eventual links between hits from DSEA study I used STRING 9.1 
database, which indicates potential and documented interaction within the group of 
genes or their protein products (http://string-db.org/).The first layer of analysis 
	
Fig. 27: Interaction network of putative GCR agonist targets.  
(A) Interactions between possible targets of GCR agonists were evaluated by STRING, which revealed network 
containing mainly TIMM proteins. (B) Minimal expansion of the network linked all candidates and revealed 
node (outlined by red oval) containing 4 chaperone proteins. 	
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indicated a strong interaction cluster of TIMM proteins without links to any other 
DSEA-derived hit (Fig. 27A). However, the minimal expansion of the network by one 
additional interaction resulted in generation of the chaperone cluster with HSPA8, 
HSP90AA1, DNAJB1 and BAG1 (Fig. 27B). The latter three proteins were detected 
as putative interactors of ATP7B-WT and ATP7B-H1069Q in SILAC experiments. 
Thus, their role in GCR agonist-mediated rescue of ATP7B mutant should be 
eventually addressed, although IP data did not provide solid confirmation of 
HSP90AA1 or DNAJB1 with ATP7B-H1069Q. 
 
3.3.7. Correctors of ATP7B-H1069Q mutant protect ATP7B-deficient cells from 
Cu toxicity 
My results outlined in previous sections indicate that several FDA-approved drugs 
were capable of decreasing the degradation of ATP7B-H1069Q mutant as well as its 
retention in the endoplasmic reticulum. Such impact of the compounds on the mutant 
is expected to reduce accumulation of toxic Cu in hepatic cells, which express 
ATP7B-H1069Q. To test whether this is a case I took advantage of recently developed 
hepatic cells lines, which exhibit different degree of ATP7B function loss. ATP7B 
knock out HepG2 cell line was developed using zinc finger nuclease technology 
(Chandhok et al., 2014). This cell line was used further to develop HepG2 cells stably 
expressing the 2 most frequent ATP7B mutants H1069Q and R778L (Chandhok et al., 
2016). I managed to obtain these cells shortly before the end of my PhD project and 
used them to validate efficiency of FDA-approved correctors of ATP7B mutant. 
ATP7B knockout (KO) cells as well as mutant expressing lines (H1069Q and R778L 
cells) do not resist Cu at low mM concentrations. We took advantage of this property 
of all 3 ATP7B-deficient HepG2 cell lines and treated them for 24h with 1mM Cu in 
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the absence or presence of GCR agonists, domperidone and HSP70 inhibitor to 
evaluate whether any mutant corrector improves viability of the cells in the presence 
of toxic Cu. Cell survival was analyzed using MTT assay and ATP7B KO cells, which 
stably express WT-ATP7B (WT cells), were utilized as a control in these experiments. 
Fig. 28B-D show that Cu significantly decreases viability of all 3 ATP7B-deficient 
cell lines (KO, H1069Q and R778L), while WT cells resist the same Cu levels in the 
	
Fig. 28. Impacts of FDA-approved compounds on resistance of ATP7B-deficient cells to toxic Cu.	
Survival of ATP7B-deficient cell lines after 10 µM Mometasone, Dexamethasone and Beclometasone, 1 µM 
Domperidone and 100 nM of HS-72 was analysed using MTT assay. Bar graphs indicate cell viability after 
treatment with drugs following by exposure to 1mM CuCl2 for 24h. Differences in viability between 1mM CuCl2 
treated cells and cells treated with drugs and then 1mM CuCl2 were analysed using T-test. A value of P<0.05 was 
considered significant.  All data is represented as mean ± SE of at least three independent experiments. *** - 
p<0.001, ** - p<0.01, * - p<0.05 compared to Cu-treated cells. 	
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medium (Fig. 28A). Mometasone significantly rescued viability of cells expressing 
either H1069Q or R778L mutant (Fig. 28C, D) indicating substantial resistance of 
treated cells to toxic Cu. However, mometasone unexpectedly increased resistance of 
KO cells to Cu (Fig. 28B). This indicates that mometasone apparently increases cell 
tolerance to Cu through ATP7B-mutant-independent mechanism. Nevertheless, it 
could not be completely ruled out that correction of the mutant in H1069Q and R778L 
cells contributes to reduction of Cu toxicity. Further studies will be needed to 
understand the mechanism through which Mometasone counteracts Cu toxicity. 
In contrast, HS-72 and structurally similar drug domperidone failed to improve 
viability of KO cells in toxic Cu but increased survival of H1069Q cells (Fig. 28C). 
This observation suggests that both drugs require ATP7B mutant protein product to 
covey resistance to Cu and, hence, rescue function of ATP7B-H1069Q mutant. HSP 
inhibitor exhibited positive trend in R778L cells as well (Fig. 28D), although the 
changes in cell viability were not statistically significant. Testing the panel of different 
Domperidone concentrations could potentially help to achieve R778L rescue with this 
drug. Indeed, we reduced significantly the concentration of HS-72 (from 50 µM to 
100 nM) to avoid its toxicity. Yet the inhibitor was effective in recuing the function of 
ATP7B mutants. Thus this HSP70 inhibitor emerges as potential candidate for 
development of new therapeutic approach for WD. In the mean time Domperidone 
has been already in therapeutic use for epigastric pain, nausea, and vomiting (Robbins 
et al., 2016). Thus its translation into use for WD patients carrying H1069Q mutation 
could be really fast. Mometasone represents another FDA-approved compound that 
deserves consideration for WD cure, although the mechanism of its action in ATP7B-
deficient hepatocytes has to be further investigated.  
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CONCLUDING REMARKS 
 
 
In this study the new target and drugs for correction of the most frequent H1069Q 
mutant of ATP7B were revealed. On one side, this opens new opportunities for 
development of mutant correction-based therapies, while on the other expands the 
background for the further research on the proteostatic regulation of pathogenic 
mutants of ATP7B and other disease-associated misfolded proteins.  
Analysing the interactome of WT and H1069Q variants of ATP7B, HSP70 was 
revealed as a potential target for correction of the ATP7B mutant. Despite the 
exceptional importance of HSP70 for a number of vitally important processes (protein 
folding, transport, signaling, e.g.) (Bukau et al., 2006; Frydman, 2001; Hartl et al., 
2011; Mayer and Bukau, 2005) the search for safe drugs that suppress HSP70 
provided me with several candidates for ATP7B mutant correction and then with 
validated leads, which can be explored in preclinical studies. This underscores the 
efficiency and potential of the strategy, which combines proteomics and 
bioinformatics for drug discovery.  
The main findings of my project suggest that HSP70 may represent an effective target 
for correction of ATP7B-H1069Q mutant. It will be important to understand whether 
this target can be also utilized to rescue other WD-causing ATP7B variants. It turns 
out that others chemical inhibitors that improve localization and function of ATP7B-
H1069Q have the same impact on the group of other ATP7B mutants (Chesi et al., 
2016). Thus, the potential of HS-72 and Domperidone for correction of other ER-
retained ATP7B variants has to be explored. However, even if only few ATP7B 
isoforms will be corrected by the HSP70-specific drugs, this should also be 
considered as a positive outcome. Indeed, selectivity of these compounds for 
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restricted number of mutants would indicate a specific impact on a limited subset of 
quality control mechanisms, which does not compromise entire cell proteostasis. Such 
specific impact would be especially valuable in the context of emerging concept of 
“personalized medicine”, which requires tacking in account a particular genetic 
background of the individual patient to develop appropriate treatment strategy 
(Spagnolo et al., 2017).  
In addition to ATP7B mutants, the potential of HSP70-specific drugs has to be 
explored for other diseases. HSP70 involvement in ER retention and degradation of 
cystic fibrosis-causing ΔF508 CFTR mutant is well documented (Young, 2014). A 
growing body of evidence also supports the role of the HSP70 chaperone system in 
other disorders caused by misfolding and aberrant trafficking of such ion channels as 
the CFTR chloride channel in cystic fibrosis and the hERG potassium channel in 
cardiac long QT syndrome type 2 (Young, 2014). Thus, targeting HSP70 for rescue of 
these ER-retained ion transporters appears to be a valuable strategy. 
Finally, my findings suggest that mutant correction can be considered as an option for 
development of new therapeutic approach for WD cure. The treatment of WD mainly 
remains based on two strategies: increasing Cu excretion using chelators and reducing 
Cu absorption from the diet by treatment with Zn salts (Ala et al., 2007). Both 
therapies have own limitations and, hence, development of additional and/or 
alternative therapeutic strategies for WD is highly demanded (Ferenci, 2006; Roberts 
et al., 2008). This study indicates that some FDA-approved drugs rescue function of 
the most frequent ATP7B mutant in vitro. It is expected that the use of these 
compounds might be beneficial for a large group of patients with WD. Certainly, the 
efficiency of the drugs has to be validated in other WD models, namely: in mice with 
ATP7B mutant knock in and in hepatic cells reprogramed from patient fibroblasts. On 
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the other hand, such FDA-approved compound as domperidone has really low 
toxicities and side effects (Leeser and Bateman, 1985 ; Ortiz et al., 2015; Robbins et 
al., 2016; Schey et al., 2016) and, therefore, can be quite rapidly repurposed for WD 
cure. Thus, I hope that translation of my cell biology findings into preclinical and 
clinical studies will pave a way for new therapeutic strategies to combat Wilson 
disease.  
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